Characterization of dissociative anesthetics acting at the NMDA receptor site by Kang, HyeWon Heather
                          
This electronic thesis or dissertation has been
downloaded from Explore Bristol Research,
http://research-information.bristol.ac.uk
Author:
Kang, HyeWon  Heather
Title:
Characterization of dissociative anesthetics acting at the NMDA receptor site
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
                          
This electronic thesis or dissertation has been
downloaded from Explore Bristol Research,
http://research-information.bristol.ac.uk
Author:
Kang, HyeWon  Heather
Title:
Characterization of dissociative anesthetics acting at the NMDA receptor site
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
—————————————————————————————————————  
Characterization of dissociative anesthetics acting at the 
NMDA receptor site 
————————————————————————————————————— ————————————————————————————————————— 
By 
Heather Hyewon Kang 
Department of Bristol Medical School 
University of Bristol 
A dissertation submitted to the University of Bristol in accordance with the requirements for 
award of the degree of DOCTOR OF PHILOSOPHY in the Faculty of Health Sciences. 
March 2019 
Word count: 35,640  

Abstract 
 Glutamate receptor is considered to be the most fundamental 
neurotransmitter in the human body. It is responsible for the fast excitatory 
neurotransmission in the central nervous system and is involved in the synaptic 
plasticity modulation. Many glutamate receptors are considered as therapeutic target 
sites for neuropsychiatric diseases such as Alzheimer’s disease, epilepsy, 
schizophrenia and major depression disorder. For example, ketamine, one of the 
noncompetitive NMDA receptor antagonist exhibits remarkable rapid and sustaining 
antidepressant effects. However, these compounds also exhibited adverse 
dissociative effects and raised the issue of abuse liability.  
 Since there are colossal potentials for NMDA receptor related compounds to 
become therapeutic targets for severe neurological disorders with significant unmet 
needs, pharmacokinetic profiling of dissociative antagonists could help eliminating 
these adverse effects when producing effective and safe novel drug targets. 
 In this study, several psychotomimetic effects yielding NMDA receptor 
antagonists including some of the low-profile designer drugs such as diphenidine and 
its derivatives as well as ephenidine, which became very popular over their 
ketamine-like hallucinating property, have been studied via receptor binding assays, 
as well as pre-pulse inhibition behavior tests to measure the sensory motor gating 
properties. Their ability to affect NMDA receptor mediating fEPSPs and synaptic 
strength has also been examined via electrophysiological methods such as in vitro 
field recording and whole cell patch clamp recording.  
 It has been demonstrated that these designer drugs are selective, potent and 
voltage-dependent NMDA receptor antagonist via pharmacological and 
electrophysiological methods. Synaptic plasticity modulating effect of ketamine, D-
AP5, memantine and ephenidine as well as ketamine’s metabolite (2S,6S)- and (2R,
6R)-HNK have also been investigated in the present study.  
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Chapter 1. 
Introduction  
1.0. General introduction 
 This dissertation concerns the pharmacology of some new recreational 
drugs that have been introduced to the public as ‘legal highs’. Some are being abused 
for their ‘dissociative’ effects in man. They have similarities to ketamine, a 
‘dissociative anesthetic’, which is known to alter glutamate-mediated synaptic 
transmission in the brain. The basic aim for the present study is to understand 
whether and how these new drugs interact with synaptic transmission. Therefore, this 
Introduction will provide the background information on glutamate receptors and on 
dissociative anesthetics including their therapeutic and recreational uses.  
Chapter 1. Introduction
1.1. Glutamate receptors 
By the mid-1990s approximately 300 types of transmitter molecules had been 
identified and shown to exist in the human brain. Among these, glutamate receptors, 
predominantly activated by glutamate, take part in the mediation of the major fast 
excitatory synaptic transmission and these receptors are located in the neuronal 
membrane where drugs may act (Sommer et al., 1992). The journey of glutamate 
receptor discovery begins from the 1950s, when Berl and Waelsch demonstrated the 
existence of high levels of L-glutamate and L-aspartate throughout the whole brain 
(Berl & Waelsch, 1958) which were separately shown to have a role in evoking 
depolarization in crayfish muscle (Harreveld, 1959). 
 Thanks to these discoveries and early research works, glutamate receptors 
are now known to be important in neuronal communication, memory acquisition and 
storage (Collingridge et al., 1983; Morris et al., 1986). These receptors are widely 
recognized as significant therapeutic targets for neuropsychiatric diseases (e.g., mood 
disorders, schizophrenia, epilepsy and Alzheimer’s disease) (Kornhuber & Weller, 
1997).  
Glutamate receptors can be categorized into two functional classes according 
to their mechanism of actions. The first class of receptors is ionotropic glutamate 
receptor (iGluR). iGluR is a ligand-gated ion channel that allows fast acting neuronal 
communication (Sugiyama et al., 1987). The second class of receptors is 
metabotropic glutamate receptor (mGluR). mGluR is coupled to guanine nucleotide-
binding proteins (G-proteins), which contributes to its relatively slow and long-
lasting neuronal activity changes (Sugiyama et al., 1989). The types and structures of 
iGluRs and mGluRs are compared in Fig. 1 (figure from Kandel et al., 1991).  
1.1.1. Ionotropic receptor (iGluR) 
iGluRs are tetramers composed of different combinations of glutamate 
receptor subunits (Ciabarra et al., 1995). Each consists of a cation channel pore. 
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These channel pores can be activated and open when specific types of agonist 
molecule binds to the channel (Watkins and Evans, 1981). The receptor is mostly 
comprised of various subunits that shape the internal channel pore domain with 
several binding sites, which regulate the neuronal excitability by controlling the ion 
flow (Eccles & McGeer, 1979). Main types of ions that pass through the center of the 
receptor complex are sodium [Na+], potassium [K+], and calcium [Ca2+]. Once 
ligands such as neurotransmitters or drugs bind to one or more of the iGluR binding 
sites, the configuration of the channel alters (Monaghan et al., 1988). Regulation of 
the amount of ion flow is dependent on this transformation of the channel pore 
shape. Depending on the occupied sites, ligands could open the pore to grant 
permeation of selected ions or inhibit the receptor activation (Henley et al., 1989). 
Direct connection of the binding sites to the ion channel allows the onset of gating to 
be very rapid (Dale & Roberts, 1985).  
1.1.1.1. Types of agonistic and antagonistic activation of iGluR 
 There are different types of ligands that gate these channels by modifying 
the receptor configuration and inducing partial or full agonism or antagonism 
(Monaghan et al., 1988). If binding of specific ligands produce a maximal level of 
ion flow and induce complete opening of the channel, it is considered a full agonist, 
whereas ligands which participate in increasing the level of the flow of ions, but not 
to the maximal degree are considered partial agonists. Those that do not show 
functional modification of basal activity even if they bind to the neurotransmitter-
binding sites are called competitive antagonists since their existence on the binding 
sites blocks the ability of agonists to produce any effect by binding to the occupied 
sites (Trynelis et al., 2010).  
1.1.1.2. Groups of iGluR 
 There are three groups of iGluR; α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate receptors (AMPARs), kainate receptors (KARs) and N-methyl-
D-aspartate receptors (NMDARs) (Watkins & Evans, 1981; Kehl & McLennan, 
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1983). The first two subtypes of receptors, collectively called non-NMDA receptors, 
control fast excitatory synaptic currents while NMDARs mediate relatively slower 
and longer sustaining synaptic transmission. These groups were determined by 
differential selectivity to key agonists and antagonists (McLennan & Lodge, 1979). 
1.1.1.2.1. Early pharmacological classification of iGluR subtypes 
 It was not until the 1980s that the concept of currently well accepted 
glutamate receptor subgroups, NMDAR, AMPAR and KARs, was settled. In the 
1970s and 80s, potent excitants, such as kainate (Shinozaki & Konishi, 1970) and 
quisqualate (Shinozaki & Izumi, 1974) as well as weakly selective glutamate 
receptor antagonists, such as glutamic acid diethyl ester (GDEE) and D-ɑ-
aminoadipate (DɑAA), were discovered to display glutamate and aspartate-induced 
excitation (Haldeman & McLennan, 1972l; Biscoe et al., 1977). Many of these early 
studies strongly indicated the separation between NMDARs and non-NMDARs for 
the synaptic transmitters such as L-glutamate and L-aspartate (McLennan & Lodge, 
1979; Davies et al., 1981; Watkins & Evans, 1981; Davies & Watkins, 1985). The 
reason why AMPAR and KAR were collectively called non-NMDA receptors in the 
early days was due to a limitation of the pharmacological tools to differentiate these 
receptors. This was continued until studies such as those by Davies and Watkins in 
1981, which suggested the concept of separation of quisqualate and KAR by 
demonstrating the discriminating effect of DGG as well as LGG between kainate and 
quisqualate-induced excitation. Both compounds showed much higher antagonistic 
effects towards kainate-mediated responses (Davies et al., 1981).  
1.1.1.2.2. AMPA receptor (AMPAR) 
 The AMPAR was originally known as the quisqualate receptor, named after 
a plant component, quisqualic acid (Shinozaki & Izumi, 1974). In 1982, “AMPA” 
was developed and proven to be greatly potent and selective agonist for this 
glutamate receptor subtype (Honoré et al., 1982), hence the name changed to AMPA 
receptor, accordingly.  
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 AMPARs are tetramers of subunits; GluA1-4. The subunits are usually 
combined in pairs, e.g. 2 GluA1 plus 2 GluA2 subunits (Keinänen et al., 1990). GluA 
subunits are all calcium permeable except for the edited GluA2 subunit. This unusual 
subunit controls the calcium-permeability of AMPARs, which is regulated by the Q 
(glutamine) / R (arginine) editing site of the GluA2 messenger ribonucleic acid 
(mRNA). GluA2 (Q) is the calcium permeable form whereas GluA2 (R) is a calcium 
impermeable form. Therefore, converting a single amino-acid from theGluA2 (Q) 
form to GluA2 (R) form at a channel pore domain results in the basal calcium 
impermeability of AMPAR (Higuchi et al., 2000).  
 AMPARs execute much of rapid excitatory synaptic transmission and are 
considered as the first gate of the glutamate reception in the synapse. AMPARs 
produce plasma membrane depolarization largely by promoting influx of Na+ ions 
(Bleakman & Lodge, 1998).  
 In addition, AMPAR expression change could contribute to the modulation 
of synaptic plasticity. It is plausible that enhancing the post-synaptic response 
through increasing the total number of AMPARs or increasing single channel 
conductance at the postsynaptic site could be the cellular basis of long-term 
potentiation (LTP) mechanisms (Benke et al., 1998). 
1.1.1.2.1. Kainate receptor (KAR) 
 KARs are composed of multimeric units of low-affinity GluK1-3 
(previously known as GluR5-7) subunits and high-affinity GluK4 and 5 (previously 
known as KA1 and 2) subunits (Bleakman & Lodge, 1998). Even though there are 
certain unique features of KAR, they work in a very similar mode of action as 
AMPAR. KARs are also ligand-gated ion channels, mostly enabling Na+ influx 
(Sommer et al., 1992). 
 With the help of new pharmacological tools and transgenic mice models, 
KAR’s involvement in the synaptic transmission has been recognized (Bortolotto et 
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al., 1999). Although still contentious, there have been studies suggesting that KARs 
contributes in generating mossy fiber, NMDAR-independent LTP in the cornu 
ammonis area 3 (CA3) (Castillo et al., 1997) as well as regulating synaptic plasticity 
in the somatosensory cortex (Benke, 2018) and anterior cingulate cortex (ACC) 
(Koga et al., 2015). 
Since this thesis will heavily focus on the NMDAR, details of structure, 
pharmacology and functional role of NMDARs will be dealt later in this chapter 
within separately dedicated sections.  
1.1.2. Metabotropic receptor (mGluR) 
The second class of glutamate receptors are the mGluRs which are coupled to 
a second messenger system, via G-proteins. It was not until 1985 that glutamate was 
proven to be involved in the production of molecules related to the major secondary 
messenger cascade. Sladeczek and his colleagues successfully performed an 
experiment to display the modulation by glutamate in the production of inositol 
phosphates (Sladeczek et al., 1985). This study became the foundation of the 
research on the role of the mGluRs (Sugiyama et al., 1987).  
The structure of the mGluR is composed of a long string of amino acids, 
which form seven transmembrane loops. These amino acid loops couple with G-
proteins, which are located inside of the neuron, and connected to an effector unit 
(Conn & Pin, 1997). Some of these G-proteins increase or decrease the activation of 
ion channels and act upon the target neuron to proceed a biochemical cascade 
changes (Gereau & Conn, 1995). 
There are 8 different subtypes of mGluRs which is categorized into three 
subgroups according to the sequence similarity as well as activating pathways for 
intracellular signaling transduction. Group I subgroup is composed of mGluR1 and 
mGluR5 subtypes. These receptors act mainly via phospholipase C (PLC) and 
modulate intracellular calcium signaling. Group II subgroup includes mGluR2 and 
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mGluR3 while the Group III subgroup includes mGluR4 and mGluR6-8 (Nakanishi, 
1992). Mostly, these receptors have a modulatory role (Nicoletti et al., 1986; 
Yoshimizu et al., 2006) on other receptors’ actions. mGluRs yield relatively slower 
but longer lasting effects compared to iGluRs (Traynelis et al., 2010). 
1.2. Characteristics of NMDA Receptor 
 The NMDAR is a major player in physiological synaptic transmission and 
pathophysiological developments. Since I have dedicated my practical research work 
to characterizing the NMDAR antagonists with dissociative effects, I will devote a 
major part of the Introduction chapter to discuss the fascinating properties of 
NMDARs including their major role in induction of synaptic plasticity as well as 
their involvement in many health issues. 
1.2.1. Structure of NMDAR 
The structure of NMDAR subunits is quite similar to that of other iGluRs, 
such as AMPARs and KARs, with an extracellullar N-terminus and intracellular C-
terminus and a re-entrant transmembrane domain.  The NMDARs differ from non-
NMDARs in many aspects including ion permeability and also having many binding 
sites for modulators that include zinc, magnesium, glycine/D-serine, and polyamines 
(Fig. 2). These receptors can be divided into two main subgroups, GluN1 and GluN2 
subunits, and the less understood GluN3 subunits. GluN2 subunits can then be 
subdivided into four different subtypes, GluN2A-D, which are transcribed from four 
different genes (Cull-Candy et al., 2001). Typically, the NMDAR complexes possess 
two GluN1 subunits combined with two GluN2 subunits of various subtypes to 
produce different forms of NMDAR that exert different functional and 
pharmacological properties. This variation of the tetrameric NMDAR complexes 
makes for unique actions of NMDARs at different brain regions as well as at 
different developmental stages (Paoletti & Neyton, 2007). Thus, this differential 
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GluN2 subunit expression in the complex produces multiple receptor isoforms and 
diverse pharmacological and functional properties. Also, in the late 20th century, a 
new class of subunit group GluN3A and GluN3B subunits was reported. 
1.2.1.1. Localization of NMDAR 
 When the GluN2A/B localization was examined with a polyclonal antibody, 
it was clear that these subunits were extensively spread throughout the CNS similar 
to that of GluN1, indicating existence of operative GluN1/GluN2 complexes 
(Petralia et al., 1994). When the localization patterns of GluN2A and GluN2B were 
investigated on hippocampal slices, much denser collection of these subunits were 
concentrated in the stratum oriens area compared to the molecular layer of cornu 
ammonis area 1 (CA1) and CA3, where distinctive puncta can usually be found (Fig. 
3) (Petralia et al., 1994). 
1.2.2. Pharmacology of NMDAR 
 NMDARs are highly sensitive to voltage-dependent channel block by 
endogenous Mg2+ ions (Ault et al., 1980). Mg2+ is a divalent cation constituent of all 
body fluids including the cerebrospinal fluid (CSF). It binds to the inner pore 
domain, limiting ion flow through the channel pore at resting membrane potentials 
(Mayer et al., 1984; Nowak et al., 1984; Mori & Mishina, 1995). The normal 
functioning of the NMDAR complex demands both L-glutamate, the main agonist, 
and glycine or D-serine, the co-agonist, to be bound to their respective receptor sites 
concomitantly (Johnson & Ascher, 1987; Kleckner & Dingledine, 1988; Lerma et al., 
1989; Monyer et al., 1992; Furukawa et al., 2005). Micromolar concentrations of 
glycine or D-serine are normally existent in the synaptic cleft so that its site on 
GluN1 subunit is typically occupied when the synaptically released glutamate binds 
to the GluN2 subunit. As for the NMDAR agonist, the most commonly used 
selective agonist is NMDA (Kew & Kemp, 2005). There are some other known 
agonists for NMDARs which includes Alanine, Glutamic acid (glutamate), Aspartic 
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acid (aspartate), Glycine, Serine (D-serine, L-serine), Spermidine and Quinolinic 
acid (quinolinate) (Kleckner & Dingledine, 1988; Simon et al., 1984). Especially, D-
serine has greater potency as a co-agonist than glycine (Wolosker, 2006).  
1.2.2.1.  Antagonists of NMDAR 
NMDAR grabs even more attention due to its anesthetic, hallucinogenic and 
euphoriant antagonists, which has captured the attention of people who seek to find 
recreational interests through drug abuse. These dissociative drugs include the well-
known antagonists such as ketamine, phencyclidine and dextrorphan.  
1.2.2.1.1. Competitive antagonists 
NMDAR competitive antagonists bind to the glutamate binding site. 
Examples of this type of antagonist are best represented by AP5 and AP7. (R)-2-
amino-5-phosphonopentanoate ((R)-AP5 or D-AP5), also known as D-2-amino-5-
phosphonovalerate (D-APV) is one of the most used NMDAR antagonists, thanks to 
its development by Jeff Watkins 20 years ago (Davies et al., 1981; Monaghan et al., 
2009).  
1.2.2.1.2. Glycine-site antagonists 
 There are some ligands which bind to the glycine site and block the receptor 
activation (Kvist et al., 2013). Examples are rapastinel (GLYX-13) (Burgdorf et al., 
2013) and kynurenic acid (Herberg & Rose, 1989). 
1.2.2.1.3. Uncompetitive antagonists 
In this section, I would like to elaborate more on some of the NMDAR 
channel blockers, such as phencyclidine; 1-(1-Phenylcyclohexyl)piperidine (PCP), 
ketamine and dizocilpine; [5R,10S]-[+]-5-methyl-10,11- dihydro-5H-
dibenzo[a,d]cyclohepten-5,10-imine (MK-801) that possess dissociative properties 
(Domino et al., 1965; Sircar & Zukin, 1983; Koek et al., 1988). MK-801 has the 
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highest NMDAR affinity (18 nM) so it is used in a radio labelled form to label 
NMDAR populations in brain slices (Benvenga & Spaulding, 1988). Ketamine and 
memantine have a lower affinity compared to MK-801 (Thomson et al., 1985). 
These uncompetitive antagonists are different from the non-competitive 
antagonists since in order for these antagonists to be activated, an agonist must 
activate the receptor first and open the ion channel. Then, these antagonists bind to 
an allosteric site within the channel, called ‘PCP binding site’ (Parsons et al., 1995).   
Other than aforementioned three antagonists, memantine, a drug used for 
treatment of Alzheimer’s disease is another example of an uncompetitive NMDAR 
antagonist (Parsons et al., 1999) along with dextrorphan, a de-methylated metabolite 
form of dextromethorphan (Hernandez et al., 2000). 
1.2.2.1.3.1. PCP 
PCP (CI-395) (Martin & Lodge, 1988) was synthesized on 26 March 1956 by 
a scientist named Victor Maddox of Parke Davis (Thombs, 1989). When it was tested 
on animals for its effects, researchers found distinctive properties that made PCP 
special and unique (Martin & Lodge, 1988). Its effects varied (depending on dosage) 
from ataxia to excitation to anesthesia but above all, its effect as a potent general 
anesthetic without respiratory depression was the main target of heavy investigation 
on PCP and its derivatives (West et al., 2000).  
When 10 mg/kg of PCP was administered intraperitoneally into monkeys, 
surgeons could execute laparotomies without using any other anesthetics 
(Greifenstein et al., 1958). After an adequate amount of animal toxicity testing, 
PCP’s first use as an anesthetic in patients undergoing surgeries started in 1957 at the 
Detroit Receiving Hospital by John E. Gajewski, M.D., at Parke Davis, who was 
responsible for PCP’s clinical development and Ferdinand E. Greifenstein M.D., 
Chair of Anesthesiology at Detroit Receiving Hospital (Meyer et al.,1959). Even 
though PCP’s use as a surgical anesthetic resulted in severe and extended post-
- !  -29
Chapter 1. Introduction
surgery adverse effects such as psychosis-like bizarre thought patterns and 
behaviours as well as catatonia that emerged in 10 out of the 64 patients, the FDA 
approved its use in surgical practice in 1957 and the trade name Sernyl was given to 
PCP (Morris & Wallach, 2014).  
PCP’s use as a surgical anesthetic in humans spread out widely in early 
1960s, but soon its use was discontinued because of the severe adverse effects such 
as hallucinations and delirium that emerged in 15 to 30% of the patients (Meyer et 
al., 1959). When PCP was intravenously administered to 102 patients in high doses 
(7.5 – 10 mg/kg), significant sensory deprivation occurred with appearance of 
hallucinations. This change in sensory confusion lasted up to 12-96 h post-injection 
of the drug. Many of the patients who fell into confused states of mind complained of 
severe depression, anxiety and depersonalization. Their electroencephalography 
(EEG) pattern also changed depending on the dose of the drug. After 7.5 mg of the 
drug was administered, alpha and beta activity decreased with slowing of the theta 
pattern. With high doses, theta and delta pattern increased in amplitude (Meyer et al., 
1959). In fact, now in the United States, PCP has been added to Schedule II of the 
Controlled Substance Act.  
PCP presents typical schizophrenia symptoms such as cognitive deficits and 
mental alterations so much so that one can hardly differentiate between true 
schizophrenic symptoms and PCP effects, hence Kornhuber and Weller reported that 
PCP is “best available phenocopy of schizophrenic psychosis” (Kornhuber & Weller, 
1997). The representative symptoms of PCP misuse include impaired sense of reality, 
deficits in cognitive thinking and perceptual discrimination with loss of body image. 
PCP can induce positive, negative and cognitive symptoms of schizophrenia in 
healthy subjects while enhancing these symptoms even more in schizophrenic 
patients (Wiescholleck & Manahan-Vaughan, 2013).  
1.2.2.1.3.2. Ketamine 
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Ketamine was synthesized in 1962 by research group lead by Calvin Lee 
Stevens, who were working as a chemical consultant at Parke-Davis (Morris & 
Wallach, 2014). On 3rd August, 1964, Edward Domino and Guenter Corrsen first 
treated humans with intravenous ketamine that varied from sub-anesthetic to general 
anesthetic dose (Domino, 2010). Ketamine was studied on 20 prisoner volunteers 
and proved to be an effective general anesthetic. Doses of 1.0-2.0 mg/kg of ketamine 
proved to be effective within 1 min of application and dose-dependently lasted 5-10 
min. This result was published in 1965. It was especially interesting since there was 
no evidence of tachyphylaxis and the respiratory depression was almost 
unnoticeable. Post-injection, some of the subjects complained of hypertension as 
well as psychological distress. Even though it only took approximately 10 min for 
the subjects to wake up from unconsciousness, electroencephalographic evidence 
showed that 1 to 2 h were required for subjects to be fully recovered.  
When researchers were publishing their data, they were very cautious on how 
to put this influence of ketamine in words in order for the Parke Davis company 
administrators and lawyers to permit prolongation of the ketamine development. 
They deliberated using various terms to elucidate ketamine’s unusal PCP-like 
properties with less side-effects and shorter duration (Domino et al., 1965) and came 
up with the term “dissociative anesthetic” to infer the disconnection of user’s body 
from the environment (Domino, 2010). Until now, this “dissociative” term is coined 
to explain PCP and ketamine’s effects.  
In 1982, Prof. David Lodge discovered that ketamine resulted in a selective 
inhibition of NMDARs and depressed the cat polysynaptic reflexes (Lodge et al., 
1982). After he presented his work at a symposium held in France, ketamine’s 
mechanism of action was established as an NMDAR antagonist (Lodge et al., 1982).  
A few years later, it was demonstrated that ketamine is a use- and voltage-
dependent open channel blocker. It gets trapped inside the NMDAR channels and 
forms a trapping block in a similar manner as MK-801 (MacDonald et al., 1987; 
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Huettner & Bean, 1988). Ketamine can cause deactivation of eukaryotic elongation 
factor 2 (eEF2) kinase, calmodulin-dependent protein kinase II (CaMKII) which 
decreased eEF2 phosphorylation and de-suppress protein translation of brain-derived 
neurotrophic factor (BDNF) (Kavalali & Monteggia, 2012; Autry et al., 2011).  
In 2000, ketamine received much attention for the superior rapid and 
sustained antidepressant effects compared to conventional antidepressants (Fig. 4) 
(Berman et al., 2000; Autry et al., 2011). Fascinatingly, Edward Domino, the one 
who was in charge of ketamine’s clinical development, reported in his 2010 review 
paper that back then, he ran a drug abuse screening lab. One of his patients who had 
a severe case of major depressive disorder (MDD) was heavily addicted to ketamine 
and PCP and said that these two compounds worked much better than her 
antidepressants. Although he didn’t realize what that meant at that time, ketamine’s 
antidepressant effects were there all along (Domino, 2010)! 
Other than antidepressant actions, ketamine is used for several different 
therapeutic indications as well. Patients who suffer from thanatophobia find ketamine 
treatment helpful in reducing their unnatural fear of death. One of the 
psychotomimetic effects of ketamine includes “Near Death Experience” (NDE) by 
distorting the subject’s own body image and boundary while maximizing the 
sensation of unreality. Natural NDE is known to be experienced by patients who 
actually have lost the vital signs during surgical crises such as heart attack. Patients 
who “came back to life” explain that this NDE allowed them to accept and fear less 
of death and indeed reminded them of the meaning of life. Through ketamine 
treatment, subjects allegedly experience “death” in a timeless, peaceful and calm 
dimension and this produces a steady decline in abnormal fear of death 
(Khorramzadeh & Lofty, 1973). Ketamine has also proved itself to be beneficial in 
psychotherapy for alcoholism and heroin addiction. A ketamine treatment group 
showed a significantly increased level of more than one year abstinence (about 40% 
more than traditional therapy group). Subjects who found ketamine helpful also 
mentioned their self-confidence level increased and in addition their view of life 
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became more optimistic. Pharmacologically, ketamine’s other target system, 
monoaminergic and opioidergic neurotransmissions are mainly involved in the 
pathophysiology of addiction of alcohol and heroin (Krupitsky & Grinenko, 1997).  
1.2.2.1.3.3. MK-801 
Unlike PCP and ketamine, which were first synthesized at the Parke-Davis 
company, MK-801, which is another uncompetitive and NMDAR selective potent 
antagonist (Wong et al., 1986) with stronger and longer lasting binding potency 
(Benvenga & Spaulding, 1988), was synthesized at Merck Pharmaceuticals in 1979 
by Marcia Christy and Paul Anderson. It was proven to be approximately 10 times 
more potent than PCP and 100 times higher than ketamine (Kornhuber & Weller,
1997). However, compared to these two drugs, MK-801 turned out to be less 
voltage-dependent (Frankiewicz et al., 1996). 
In animal testing, MK-801 was found to possess a uniquely potent 
anticonvulsant property (Clineschmidt et al., 1982). MK-801 binds to the PCP 
binding site inside the pore of the NMDAR receptor (Wong et al., 1986) and 
enhances the expression level of extracellular dopamine receptors and DA neuronal 
firing rates while inducing NMDAR inhibition (Healy & Meador-Woodruff, 1996; 
Zhang et al., 1992). MK-801 mediated severe neurotoxic damage and produced 
intracytoplasmic vacuolization to neuronal cells (Olney et al., 1991). Also, a single 
dose (0.07-0.33 mg/kg) of MK-801 administration resulted in malfunction of 
locomotor activity, stereotypy (Heale & Harley, 1990; Tiedtke et al., 1990; Dai et al., 
1995), deficits in social interaction, learning and memory (especially hippocampal-
dependent spatial memory) (Verma & Moghaddam, 1996; Murray & Ridley, 1997; 
Zou et al., 2008). 
In electrophysiology studies, MK-801 blocked induction of hippocampus-
dependent LTP (Abraham & Mason, 1988) while increasing gamma oscillations 
frequency (Kittelberger et al., 2011) and neuronal activations in limbic structures 
(Duncan et al., 1999). 
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On the online forum for recreational drug experience, MK-801 users 
mentioned that the drug elicited “telepathic abilities” with auditory and visual 
hallucinations. It also impaired speech fluency, sense of reality and memory (Morris 
& Wallach, 2014). Therefore, MK-801 is referred to as the “cognition impairer”. 
Furthermore, it could produce symptoms that are very typical and similar to 
schizophrenia and psychosis including all positive, negative and cognitive 
symptoms.  
1.2.3. Properties of NMDAR 
Thanks to Professor Jeff C. Watkins and colleagues, who synthesized NMDA 
in the 1960s (Watkins & Jane, 2009), a large number of researchers have been 
studying NMDAR properties and NMDAR’s presence in the process of synaptic 
transmission, synaptic plasticity and neurodegeneration has been investigated 
(Yamakura & Shimoji, 1999; Davies & Watkins, 1979). 
1.2.3.1. Role of NMDAR in synaptic transmission  
Synaptic transmission is comprised of a series of processes. First, action 
potential occurs, which allows Ca2+ influx in the presynaptic site to release 
neurotransmitters; in this case, glutamate (Cushin et al., 1999). Classically, these 
released neurotransmitters diffuse into the synaptic cleft between two neurons. At the 
synaptic cleft, neurotransmitters bind to the postsynaptic receptors which leads to 
depolarisation of the target neuron. The excitatory postsynaptic potential (EPSP) in 
hippocampal CA1 area consists of AMPAR- and NMDAR-mediated currents (Blake 
et al., 1989). The AMPAR contributes mainly to the fast excitatory postsynaptic 
current (EPSC) that lasts for a short period of time (Traynelis et al., 2010). On the 
other hand, at basal levels, the NMDAR is blocked by Mg2+ but once AMPAR 
activation or other factors depolarise the post-synaptic cell, the Mg2+ ion block is 
relieved and the resulting NMDAR activation allows the inward flow of Na+ as well 
as Ca2+ into the post-synaptic neuron (Mayer et al., 1984). This depolarizes the 
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neuron further and initiates a signaling cascade. This unique feature of voltage-
dependence and high Ca2+ permeability is considered as an operative flagpole of 
NMDARs for concurring excitatory current and results in longer sustaining synaptic 
transmission (Schoepp et al., 1995).  
It should be noted that there are synaptic and extrasynaptic NMDARs which 
could be activated by the released transmitter and which may modulate the activation 
of this cell. This balanced functioning of NMDARs located at synaptic and 
extrasynaptic locations is believed to play essential role in mediating the course of 
fast excitatory synaptic transmission (Papouin et al., 2012). 
Collective evidence is suggestive of functional dichotomy between synaptic 
and extrasynaptic NMDARs; neuroprotective and neurotoxic roles, respectively. 
These two types of NMDARs are believed to have separate intracellular signalling 
pathways, hence different signalling functions (Léveillé et al., 2008; Hardingham & 
Bading, 2010). They even have different endogenous co-agonists to activate them, 
D-serine for synaptic NMDAR and glycine for extrasynaptic NMDAR (Papouin et 
al., 2012).   
1.2.3.1.1. Synaptic NMDAR 
The synaptic NMDAR has several functions. Its main role is to produce 
intracellular Ca2+ influx. At basal levels, glutamate binds to synaptic NMDARs to 
trigger normal neurotransmission. Synaptic NMDARs also play a modulatory role of 
LTP induction whereas long-term depression (LTD) involves both synaptic and 
extrasynaptic NMDAR activation. Also, a crucial role in neuronal excitation by 
activating mitogen-activated protein kinase (MAPK) and cyclic adenosine 
monophosphate (cAMP) response element-binding protein (CREB) has been 
reported as well as enhancing brain-derived neurotrophic factor (BDNF) level, 
hence, contributing to neuronal health and longevity (Hardingham et al., 2002; 
Léveillé et al., 2008). Thus, overall, synaptic NMDARs have neuroprotective 
properties (Wang et al., 2013).  
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1.2.3.1.2. Extrasynaptic NMDAR 
An emerging consensus is that the extrasynaptic NMDARs produce neuronal 
death. It was already demonstrated that the overstimulation of NMDARs participates 
in neuronal loss (Simon et al., 1984). Recently, it has been shown that if too much 
Ca2+ influx occurs by overstimulation of extrasynaptic NMDARs, neuronal 
excitotoxicity may result (Hardingham et al., 2010), which could underlie the 
fundamental pathology of neurodegenerative diseases such as Alzheimer’s disease 
(Wallace, 2014).  
There are also other factors that participate in NMDAR-mediated 
neurotoxicity. For instance, in early postnatal period, a broad developmental switch 
from GluN2B to GluN2A containing tetramers occurs. This subunit switch is 
involved in the developmental changes in NMDAR-based neurotoxicity (Laube et 
al., 1997; Zhou & Baudry, 2006). But evidence of extrasynaptic NMDAR 
involvement to promote neuronal death and resulting in the pathologies of several 
neuronal degenerative disorders such as Alzheimer’s disease and Huntington’s 
disease have been growing (Parsons & Raymond, 2014; Li et al., 2011b; Milnerwood 
et al., 2010). Thus, theoretically, it would be reasonable to target overactivation of 
extrasynaptic NMDAR as a therapeutic target. But extra caution must be taken when 
antagonists are used for clinical purposes not to conflict the normal functional role of 
NMDAR. 
1.2.3.2. Role of NMDAR in synaptic plasticity 
The NMDAR modulates synaptic plasticity in various forms such as LTP and 
LTD, processes which are known to be the cellular basis of learning and memory 
acquisition and storage (Collingridge et al., 1983; Morris et al., 1986). In 1983, Dr. 
Collingridge and his colleagues revealed the importance of the NMDAR in synaptic 
plasticity within the hippocampus (Collingridge et al., 1983) with the use of the 
highly selective NMDAR antagonist DL-2-amino-5-phosphono-pentanoate (AP5) 
(Davies et al., 1981).  Later it was discovered that this synaptic modulatory role of 
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NMDARs could impact spatial learning ability (Morris et al., 1986). Since the 
NMDAR is a key regulator of synaptic plasticity, inhibition of NMDAR-mediated 
synaptic currents by antagonists could impair synaptic plasticity and cause other 
adverse complications (Kavalali & Monteggia, 2012). As stated above, it has been 
suggested that only the synaptic NMDAR is likely to influence LTP whereas LTD 
seems to require both synaptic and extrasynaptic NMDARs (Liu et al., 2013). Great 
numbers of experiments with other NMDAR antagonists like ketamine, PCP and 
MK-801 added to this clear evidence showing the central role of NMDA receptors in 
synaptic plasticity. 
1.2.3.2.1. LTP and LTD 
Depending on the impulse train received, the effect on post-synaptic function 
differs. For instance, in response to the high-frequency stimulation, NMDARs trigger 
CaMKII activation and modulation of GluA1 subunit-containing AMPAR function in 
order to induce LTP. Low-frequency stimulation could activate hippocalcin, which 
helps a clathrin adaptor protein 2 (AP2) to bind to GluA2 AMPAR subunits to induce 
their internalization for LTD (Chen et al., 1998; Park et al., 2016).  
 There are several studies that showed NMDAR antagonists inhibiting the 
induction of LTP. For instance, the same year that the Collingridge paper on 
NMDAR’s importance in synaptic plasticity was published, separate researchers 
Stringer and Guyenet without knowing Collingridge’s work, discovered that 6 mg/kg 
of PCP or 30 mg/kg ketamine decreased LTP in rat hippocampus in vivo (Stringer & 
Guyenet, 1983). An in vitro mouse study revealed that theta burst stimulation-
mediated LTP was not affected with 1 and 10 µM doses of ketamine but was 
inhibited with a 30 µM dose (Huang et al., 2016). However, ketamine’s contribution 
to synaptic plasticity modulation is not without any controversy. In a study by 
Williams and Schatzberg in 2016, ketamine acted on presynaptic glutamate release 
enhancement, which increased LTP (Williams & Scgatzberg, 2016). Also, one of the 
in vivo studies carried out independently showed that a single dose of intraperitoneal 
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(IP) injection of 30 mg/kg ketamine increased the level of LTP in the hippocampus 
even 24 h post-injection. However, 10 µM of ketamine decreased LTP when applied 
directly on to the hippocampal acute slice (Graef et al., 2015).  
Similar to ketamine’s effect on synaptic plasticity, PCP also affects LTP 
(Stringer et al., 1983). In another paper published in the year of 1983, Stringer and 
colleagues reported that both in vivo and in vitro, PCP treatment blocked LTP 
(Stringer & Guyenet, 1983). PCP did not cause any reduction in the amplitude of the 
population spike while blocking LTP (ED50: 2-4 mg/kg). The authours (Stringer and 
Guyenet) suggested that since the input-output curve presented a dose-dependent 
shift to the right, this was due to the reduction in the probability of individual 
neuronal firing (Stringer et al., 1983). Eventually this synaptic plasticity change 
caused impaired memory (Nomura et al., 2016).  
Furthermore, MK-801, a highly potent NMDAR antagonist also produces 
hippocampal LTP inhibition. The MK-801 binding site was most dense in the 
hippocampal formation (Coan et al., 1987) and a single high dose (5 mg/kg) of 
MK-801 i.p. injection to rats suppressed LTP and produced severe impairments in 
behavioural and cognitive function even after 24 h post-injection (Wöhrl et al., 
2007). This synaptic plasticity inhibitory effect of MK-801 could be rescued by 
subcutaneous injection of neuroligin or neurolide-1, a postsynaptic molecule which 
regulates appropriate development of excitatory and inhibitory synapses via 
phosphyrolyation of the GluN1 subunit containing NMDAR (Korshunova et al., 
2015). 
1.3. NMDAR related neuropsychiatric disorders 
With all these proven properties of the NMDAR in modulating synaptic 
transmission and synaptic plasticity, the clinical importance of the NMDAR in 
neurological conditions has made this receptor a focus for therapeutic studies 
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(Dingledine et al., 1999; Lodge et al., 2009). For instance, as mentioned earlier, 
memantine produced by Eli Lilly and company in 1963 was later discovered by the 
German company, Merz, to have a therapeutic application for Alzheimer’s disease 
(Sonkusare et al., 2005; Parsons et al., 1995). D-AP5 and its heptanoate homologue, 
D-2-amino-7-phosphonoheptanoic acid (D-AP7) demonstrated their clinical potential 
in pain (Jacquet, 1988) as well as in epilepsy (Croucher et al., 1982) and ischaemic 
neurodegeneration (Simon et al., 1984). These early investigations resulted in 
considerable synthetic activity in the search for novel NMDAR antagonists in the 
industry as well as academia (Lodge, 2009). 
1.3.1. Schizophrenia 
After chloropromazine, an antipsychotic drug that blocks dopamine D2-
receptors was discovered 50 years ago, D2-receptors became the main target for the 
conventional antipsychotics for the treatment of schizophrenia (Kapur & Seeman, 
2002). However, most of these drugs target the positive (hallucinations and delirium) 
symptoms of schizophrenia and psychosis while negative (anhedonia, affective 
flattening) and cognitive (attentional disorientation and memory deficits) symptoms, 
that schizophrenic patients find very burdensome, are not relieved (Carpenter & 
Koenig, 2007). Also, a combination of antipsychotics and psychiatric therapy seems 
to lift the acute symptoms of psychosis at the beginning, but relapse rates are very 
high (up to 80%). Furthermore, vicious cycles of remission and exacerbation with 
serious side effects raise the probability of patients rejecting the treatment all 
together (Tamminga, 2008). Therefore, it is only logical to search for novel 
therapeutics with better efficacies.  
1.3.1.1. Evidence for a glutamate hypothesis in human studies 
There is a strong body of evidence in human studies supporting the 
importance of balance in glutamatergic neurotransmission for psychosis and 
schizophrenia pathogenesis (Meyer et al., 1959; Luby et al., 1959). For instance, PCP 
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could produce similar symptoms of schizophrenia in healthy volunteers. A single 
treatment of PCP in healthy human volunteers induced schizophrenia-like symptoms 
who recovered quickly whereas the same treatment to schizophrenic patients 
produced enhanced positive and negative effects which lasted much longer (up to in 
the order of weeks) (Sams-Dodd, 1999). Also, in the brain of schizophrenia patients, 
the level of GluN1 and GluN2B mRNA expression level differed in the subregions of 
the hippocampus compared to a healthy control group. GluN1 mRNA level was 
reduced and GluN2B mRNA level was found elevated in the schizophrenic patients. 
Because the GluN1 subunit is required for the receptor to be activated fully, 
decreased level of GluN1 subunits in the hippocampus of schizophrenia patients 
might be suggestive of a functional impairment of NMDAR transmission, producing 
decreased synaptic transmission within the hippocampus (Gao et al., 2000).  
1.3.1.2. Evidence for a glutamate hypothesis in non-human studies 
In parallel to human studies, when NMDARs were blocked in animal brains, 
psychosis-related symptoms occurred in both cognitive function and behaviour of the 
animal as well as the molecular and cellular system of the drug-treated brain. 
MK-801, the most potent psychosis-related drug amongst NMDAR antagonists has 
been reported to elicit hyper-locomotion and social withdrawal, which could be 
representing the positive and negative symptoms of schizophrenia (Rung et al., 
2005).  
Also, genetically modified mouse strains with 40-50% reduced GluN1 in 
cortical and hippocampal interneurons in the early postnatal window displayed a 
constellation of schizophrenia symptoms after adolescence. Behavioural changes 
such as novelty-induced hyperlocomotion, anhedonia, social withdrawal and anxiety 
could be seen as well as severe deficits in social and spatial memory. This phenotype 
was not induced when GluN1 deletion was delayed until the post-adolescent period 
(Belforte et al., 2009).  
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To collect all these non-human and human study results and draw a 
conclusion regarding schizophrenia research, NMDARs are decreased in the 
hippocampus (Gao et al., 2000), which impairs the normal function of synaptic 
plasticity (Lisman et al., 2008).  
1.3.2. Depression 
According to the World Health Organization (WHO), it was reported that 
more than 350 million people suffer from depression regardless of age. Most of the 
conventional antidepressants target the monoamine systems in the brain (Duman & 
Monteggia, 2006). However, these medications have problems with delayed onset of 
effect (usually 2 to 4 weeks) and high relapse rate. It is known that only a few 
patients show response to the drug to a first trial while in some patients, depression is 
resistant to these treatments even after multiple therapies. This type of depression is 
called treatment-resistant depression (TRD) (Zarate et al., 2006). Since depression 
can lead to ideation of suicide, it is crucial to find more fast-acting antidepressant 
compounds with higher efficacy and fewer side-effects.  
Previously, there have been few studies proposing the contribution of 
NMDARs in the pathophysiology of depression. It was shown that the NMDAR 
antagonists AP7 and MK-801 could reduce the behavioural symptoms of depression 
in animal depression models such as inescapable stress (Duman et al., 1997; Trullas 
& Skolnick, 1990). However, it was the 2000 Berman et al. paper, which showed 
ketamine’s rapid and long lasting antidepressant effect that really shook the field of 
depression (Berman et al., 2000).  
1.3.2.1. Ketamine’s antidepressant effect in human studies 
Most fortunately, ketamine treatment also worked on TRD patients who do 
not respond to any treatment, including cocktails of antidepressant medications, 
psychotherapy and even extreme treatments like electroconvulsive therapy (Caddy et 
al., 2014). 
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Ketamine is most commonly administered intravenously with a sub-
anesthetic dose of 0.5 mg/kg over 40 min. There have been case reports showing 
that, even with a single intravenous (IV) dose, ketamine treatment relieved 
symptoms within few hours (Fig. 4). The effect of ketamine could peak at 24 h after 
infusion and its effect could remain up to several weeks (Berman et al., 2000). At the 
blood level concentration range between 80-150 ng/ml, ketamine manifested 
psychotomimetic and antidepressant effects (Zarate et al., 2006). This dosage caused 
ketamine’s concentration in the brain to be in between 1-10 µM (Moghaddam et al., 
1997). 
During and after ketamine infusion treatment, side effects such as 
psychotomimetic and other negative effects may appear. Hence it is necessary for the 
patients to be hospitalized at least for 24 h (Berman et al., 2000; Zarate et al., 2006). 
The unwanted adverse effects such as psychosis, impaired cognitive function and 
neurotoxicity as well as urinary tract damage caused by long term ketamine use limit 
ketamine’s suitability as an antidepressant (Fig. 5) (Liu et al., 2015a).  
1.3.2.2. Ketamine’s antidepressant effect in non-human studies   
 In animal studies, ketamine’s dissociative effects towards psychosis are 
manifested the most during early adult hood (maximal in late puberty) and rarely 
displayed at a young age. This time window of age-dependent susceptibility in rat 
was also seen in humans with ketamine-mediated psychosis (Farber et al., 1995). 
 It has been reported that ketamine and other NMDAR antagonists, such as 
Traxoprodil; (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-
propanol, (CP-101,606), Lanicemine; (1S)-1-Phenyl-2-pyridin-2-ylethanamine 
(AZD6765) and Rapastinel; (S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-
[(S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl) pyrrolidine-2-carbonyl] pyrrolidine-2-
carboxamide (GLYX-13) contribute their therapeutic effects as antidepressants in 
animal models via increasing activation of the mammalian target of rapamycin 
(mTOR) signaling pathway, which adjusts the production of synaptic proteins (Graef 
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et al., 2015). There has been a strong body of evidence showing that ketamine 
increases activation of the mTORC1 signaling cascade in the medial prefrontal 
cortex (mPFC). This causes dendritic translation of synaptic proteins, which 
progresses into growth of dendritic spines that last/remain for about a week. This 
time period is similar to the duration of ketamine’s antidepressant effect and might be 
able to help explain how a transient increase of glutamate release by ketamine results 
in such long-lasting effect (Liu et al., 2015b). When mTOR was blocked, 
synaptogenic and antidepressant effects from ketamine were ablated (Li et al., 
2011a). Thus, ketamine’s uniquely rapid antidepressant effects seem to involve direct 
and fast activation of the mTOR signaling pathway, which subsequently enhances the 
synaptic protein synthesis and spine maturation in PFC.  
 Increased activation of the mTOR signaling cascade induces an increased 
phosphorylation level of a regulator of protein translation, eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1) and the activation of ERK, protein 
kinase B (PKB)/Akt, ribosomal protein S6 (p70S6) kinase, which was blocked by 
pretreatment with 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione 
(NBQX; AMPAR antagonist) (MacDonald et al., 1987). This signaling cascade 
projects to a consequent rise in the level of synaptogenesis (Duman et al., 2016). 
Also, the density of synaptic spines enlarges while the levels of markers such as 
synapsin 1, PSD-95 and GluR1 from both the pre- and post-synapse increases (Li et 
al., 2010). Furthermore, blocking NMDARs with ketamine deactivates eEF2 kinase 
and decreases its phosphorylation, hence the subsequent improvement of BDNF 
translation can occur. In rats, an increased level of BDNF has also been found in the 
hippocampus and in the circulatory system after ketamine treatment (Tedesco et al., 
2013). Based on this knowledge, different drugs, such as R-(R,S)--(4-
hydroxyphenyl)--methyl-4-(phenylmethyl)-1-piperidine propranol (RO25-6981; 
another GluN2B selective antagonist), AMPAR potentiator and BDNF agonists were 
tested on laboratory animals using the forced swim test (FST) and showed a similar 
rapid antidepressant behavioural effect (Ghasemi et al., 2009). mGluR2/3s are 
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presynaptic glutamate autoreceptors and control the release of glutamate. Its 
antagonists, such as (2S)-2-amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-
yl)propanoic acid (LY341495) (Fitzjohn et al., 1998), (1R,2R,3R,5R,6R)-2-amino-3-
(3,4-dichlorobenzyloxy)-6 fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
(MGS0039), could also improve depressive symptoms (Chaki et al., 2004). 
Scopolamine (a muscarinic receptor antagonist) also showed promising 
antidepressant effects. Scopolamine increased mTOR signalling and synaptogenesis 
in the prefrontal cortex as well as increasing extracellular glutamate levels. 
Furthermore, similar to ketamine, its actions were blocked by an AMPAR antagonist 
or a selective mTOR inhibitor (Furey & Drevets, 2006). 
Also, both  and  isoforms of glycogen synthase kinase 3 (GSK-3), a serine/
threonine protein kinase exhibited important role in ketamine’s antidepressant effect 
(Beurel et al., 2011). GSK-3 is involved in synaptic plasticity, especially LTD 
induced by activation of the NMDAR (Collingridge et al., 2010). GSK-3 affects the 
BDNF/Akt/mTOR dendritic protein translation pathway. Lithium provides an 
alternate route to long-lasting inhibition of GSK-3, thus activating the Akt/mTORC1 
signaling stream, as well as inhibition of GSK-3-mediated LTD (Collingridge, 2012). 
In parallel, co-administration of a low dose of ketamine (1 mg/kg) and a subthreshold 
dose of lithium (10 mg/kg), dosages that were ineffective when applied individually, 
showed antidepressant tendencies in FST behavioural experiments with mice. 
Furthermore, the level of mTOR signaling escalated. These effects usually continued 
for up to 1 week (Ghasemi et al., 2009). This combined activation of mTOR 
signaling by GSK-3 inhibition created as much synaptogenesis and antidepressant 
effect as a tenfold higher dose of each drug used by itself. A more selective GSK-3 
inhibitor, 3-(2,4-Dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)-1H-pyrrole-2,5-dione 
(SB216763) (2.5 mg/kg), could also potentiate ketamine’s antidepressant and 
synaptogenic effect similar to lithium (Howes et al., 2009). 
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Figure 6 summarizes some of the above-mentioned compounds that target 
glutamate receptor function directly or indirectly with similar results to those of 
ketamine. 
Discovery of ketamine’s antidepressant function opened up a whole new 
possibility of more effective compounds that target glutamatergic transmission to 
treat depression. Currently, there are about 20 antidepressant drug compounds 
targeting the NMDAR or other type of glutamate receptors including esketamine 
(JNJ-54135419) and GLYX-13 which are under development for treating depression 
(Table 1). 
1.3.3. Neurodegenerative disorders 
As mentioned earlier in this Introduction chapter, excitotoxicity, one of 
results of overstimulation of NMDARs, has been suggested to play crucial role in 
pathogenesis of neurodegenerative disorders like Alzheimer’s disease, Huntington’s 
disease, stroke and epilepsy (Cull-Candy et al., 2001). Thus, it could be beneficial to 
target overactivation of NMDARs to limit neuronal death related to these diseases. 
However, extra caution must be taken when NMDAR antagonists are used as 
treatment since NMDARs are also involved in neuronal survival in normal 
physiological conditions and particularly during development.  
Among NMDAR antagonists, memantine, a low-trapping blocker of the 
channel complex, is used as a medicinal drug to treat the cognitive deficits in 
moderate-to-severe Alzheimer’s disease (Tariot, 2006; Reisberg et al., 2017). 
Compared to other NMDAR antagonists such as ketamine and MK-801 which 
produce cognitive impairments, memantine has a lower affinity as well as more rapid 
dissociation kinetics (Parsons et al., 1999; Danysz et al., 2000; Johnson & 
Kotermanski, 2006; Kotermanski & Johnson, 2009). These different characteristics 
of memantine might be able to correct the abnormal NMDAR activation in 
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Alzheimer’s disease (Danysz et al., 2000). Also, it seems likely that memantine 
favorably works on extrasynaptic NMDARs (Léveillé et al., 2008).  
1.3.4. Anaesthetic effect and neuropathic pain 
When PCP and ketamine were synthesized, their unique short-acting 
anaesthetic effects with pronounced analgesic properties were celebrated since these 
drugs preserved circulatory and respiratory reflexes, which made them safer 
anesthetics for surgery (White et al., 1980). Their main mode of action was 
discovered to be via NMDAR antagonism (Anis et al., 1983). Even with the 
unwanted side effects of ketamine, it’s still widely used in human and animal surgery 
as a common anaesthetic.  
Related to these analgesic properties of NMDAR antagonists, great numbers 
of preclinical and clinical studies have demonstrated that blocking of NMDARs have 
impacts on neuropathic pain (Petrenko et al., 2003). In human studies, there has been 
much evidence to show that short-term treatment of neuropathic pain as well as 
prevention of hyperalgesic states is possible by targeting NMDARs. A NMDAR-
mediated imbalance of synaptic transmission in neuronal pain pathways might be 
involved in the cause of hyperalgesic states (Woolf & Salter, 2000) since ketamine 
reduced the pain generated by various causes (Visser & Schug, 2006; Rae Frances 
Bell, 2009). Also, dextromethorphan demonstrated its efficacy in phantom limb pain 
as well as in diabetic neuropathy whereas it did not show any effect on the 
postherpetic neuralgia  (Abraham et al., 2003; Weinbroum & Ben-Abraham, 2001; 
Siu & Drachtman, 2007). 
1.4. Dissociative effects and abuse liability of NMDAR 
antagonists  
NMDAR antagonists have quite unique and interesting properties. Some of 
them are used as surgical anaesthetics in animals and humans, but at the same time, 
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they produce strong dissociative effects such as hallucinations and loss of ability to 
recognize reality. Thus, these drugs are often used as party drugs and have high 
abuse liabilities. This recreational purposed administration of these drugs is very 
dangerous since some of these antagonists such as ketamine (Lodge & Anis, 1984) 
and PCP (Martin & Lodge, 1988) could cause severe brain damage such as Olney’s 
lesions if used in high concentration and result in death (Farber et al., 1995; Neill et 
al., 2010).  
1.4.1. PCP’s recreational use 
1.4.1.1. History of PCP’s recreational use 
The start of the wide spread use of NMDAR targeting drugs for recreational 
purposes appears to have started with PCP, on the street by the underground black 
market in San Francisco in 1967. Production and distribution mainly occurred in Los 
Angeles street gangs such as Crips to be traded in large cities in California and in 
Washington D.C. Even though PCP produces a similar degree of violent acts as 
alcohol, PCP is more notorious due to its bizarre characteristic behavioral 
presentations in some users (Morris & Wallach, 2014). 
1.4.1.2. Effects of PCP’s recreational use 
Since PCP has anaesthetic properties, like ketamine, PCP abusers tend to 
become impervious to pain and report that they suddenly acquired superhuman 
strength and became invincible. In addition, PCP impairs the thinking process in 
general and alters the sensation of body images and boundaries (Morris et al., 2005). 
These concomitant effects often lead to dangerous acts that can severely hurt users.  
There have been several reports of PCP users to snap handcuffs, which 
requires more than 1800 pounds per square inch force, and attacking victims around 
them including police officers. These reckless actions such as trying to stop a train 
with bare hands or mutilating themselves, climbing into a polar bear cave for a 
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picture, jumping from windows, pulling out own teeth and many more bizarre acts, 
have caused serious injuries and even death to many PCP abusers (Litovitz, 1983). 
Drowning is one of the most common causes of PCP-related fatalities. PCP seekers 
are psychologically addicted to euphoric effects and ecstatic bliss that PCP can 
provide. Dissociative effects such as out of body experience termed “astral 
projection”, loss of boundary between fantasy and reality, feelings of omnipotence, 
“sheer nothingness” and visual and auditory delusions seem to allow abusers to 
escape from reality (MacDonald et al., 1991). Experienced users report that all that 
they wished for came true and fulfilled when they used PCP. One of the most 
intriguing effects caused by PCP administration is changes in proprioception. 
Symptoms called “microscopia” and “macroscopia” alters the perception of size 
(Mozayani et al., 2003). For example, one might sense his/her head is extremely 
small and yet legs to be boundlessly long. Chronic users might not realize but 
residual effects like impaired cognitive function, depression, alterations in speech 
ability, could last from weeks to a year (Olney et al., 1989). 
1.4.1.3. Administration of PCP 
PCP can be administered by various routes: oral, intranasal, intramuscular 
and intravenous injection or inhalation. The oral administration method is not as 
common as other methods anymore even though the effects last longer. It is not easy 
to predict the right amount of dose to reach desired effects and this increases the 
possibility of overdose. Intranasal and inhalation methods can drive the onset very 
fast and the anticipated effects can be achieved more reliably. The safest and the 
most manageable method is to vaporize tiny doses at a time (Weaver, 2016). 
Pretreatment of PCP prior to or during marijuana inhalation has been reported to 
draw out extreme and intense experience (Thombs, 1989). 
1.4.1.4. Relevant dose range for PCP’s dissociative effects 
The minimal human dose of PCP that could start generating ‘desired’ effects 
is 1 mg. Low to moderate doses (5-10 mg) of PCP, which can produce a full 
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spectrum of outcomes, increases the breathing rate marginally, and blood pressure 
and pulse rate markedly. Also, impairment in muscular coordination such as 
nystagmus, ataxia and athetosis can also occur depending on dosage and route of 
administration. High doses (more than 20 mg) can severely decrease blood pressure, 
pulse rate and respiration. Quite often, these effects co-occur with nausea, vomiting 
and dizziness and sometimes with seizure (70 mg), loss of consciousness or even 
death (Morris & Wallach, 2014). Chronic users can build up tolerance rapidly and 
require more than 100 mg of PCP to get their desired effect.  
1.4.2. Ketamine’s recreational use 
1.4.2.1. History of ketamine’s recreational use 
The use of ketamine (also known as the “special K” in the party scene or on 
the street) use as a recreational drug started around the late 1970s by spiritualists and 
mind explorers and became widespread by the end of 90s for its delusional and 
hallucinatory effects such as out-of-body experience, known as the “the K Hole” 
effect. This included psychological dissociation such as feeling of disconnection 
from the user’s physical body and surroundings, hallucinations and even near-death 
experiences. Since overdose of ketamine itself or a high dosage of ketamine 
combined with other abused drugs can cause severe brain damage (Shahani et al., 
2007), it has been added to Schedule III drug under Controlled Substances Act in the 
United States in 1999 (even though it is not classified as narcotic) due to similar 
adverse effects as PCP. However, even nowadays, ketamine’s use in the surgical 
anesthetic in both human and veterinary practice occurs. 
The source of ketamine distribution is illicit spread of prescribed drugs 
(Persson, 2013). Most of the illegal import of the US product is known to arrive from 
Mexico. In 2000, US Drug Abuse Warning Network reported that 74% of ketamine 
misuse emergencies, were from teenagers and young adults (age between 12 to 25).  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1.4.2.2. Effects of ketamine’s recreational use 
Experienced users of ketamine have reported on the internet forum that in the 
beginning, they feel a tremendous amount of relaxation, floating sensation, which is 
the aforementioned “out-of-body” or “K-hole” experience (Moghaddam et al., 1997). 
At this stage, users are nearly completely sedated and feel their soul to be detached 
and disconnected from their own body and reality (Krupitsky & Grinenko, 1997). 
Furthermore, powerful visual and auditory hallucinations occur. If the drug is taken 
while the individual’s state of mind is unstable and disturbed, these hallucinations 
can be very unpleasant and even terrifying since the pleasantness of hallucination is 
profoundly related to the user’s emotion at the time of the drug consumption (Lodge 
& Mercier, 2015).  
 Other than this “K Hole” effect and similarity to PCP, ketamine’s analgesic 
property impairs the user’s ability to realize pain, which is why there have been 
many incidents of severe injuries after ketamine use. It is this anesthetic nature of 
ketamine in addition to its odourless and colourless properties that gained notorious 
popularity on its misuse by sexual predators as a “date rape drug” (Chu et al., 2008).  
However, one of the most interesting experiences ketamine users testified to 
was that the matter of life and death was completely indifferent to them. According 
to one of the users, “If you have a full-blown experience of K, you can never believe 
there is death, or that death can possibly influence who you are.” (Jansen, 1993). 
These users find such experiences comforting and become psychologically 
dependent on ketamine use. Ketamine also develops physical dependence with 
withdrawal symptoms such as chills, cravings, excessive sweating and even 
hallucinations in chronic addicts (Domino, 2010).  
1.4.2.3. Adverse effects from ketamine abuse 
Among many of ketamine’s adverse side effects, urinary tract toxicity is one 
of the worst symptoms that last for a long period of time (Chu et al., 2008; Chen et 
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al., 2018). In 2011, a clinical review reported more than 110 cases of ketamine-
mediated urinary tract toxicity (termed “ketamine-induced vesicopathy”) from 
chronic ketamine users. Urinary tract damage is associated with severe abdominal 
pain, which is related to reduced volume of bladder, sudden urges to urinate, and 
thickening of the bladder walls. This may result in the need for bladder removal or in 
kidney failure, if not treated within the right timeline. The only known effective 
treatment is to stop ketamine use (Chen et al., 2018). 
Other than urinary tract toxicity, ketamine abuse induces delirium, chest pain, 
severe respiratory depression, increased level of heart rate and blood pressure, 
impairment in coordination and movement, amnesia, confusion and loss of 
consciousness, which may last up to 24 h even after drug is out of the system 
(Jansen, 2011). Not common, but death from overdose also has been reported. Also, 
nausea and vomiting could co-occur with confusion and impaired motor function, 
which is extremely dangerous for choking hazard.  
 There is no antidote for ketamine overdose (Lotfy et al., 1970). It is usually 
treated with symptomatic care at the hospital as needed. Another difficult condition 
comes from not knowing which other drugs have been mixed and consumed with 
ketamine. 3,4-methylenedioxymethamphetamine (MDMA), known as ecstasy, is one 
of the main drugs cut with ketamine powder. Marijuana is also smoked together with 
ketamine (Freese et al., 2002).  
1.4.2.4. Administration of ketamine 
 Ketamine is usually consumed in clear liquid or white/off-white powder 
form and very often mixed with other drugs. Methods of ingestion route are similar 
to that of PCP; oral, intranasal, inhalation or faster onset methods such as 
intravenous and intramuscular injection. 1 to 2 mg/kg dosage can generate desired 
dissociative effects which last up to 1 to 2 h. Onset time mainly depends on the 
dosage and methods used for intake. Intravenous and intramuscular injection of 
liquid form of ketamine can induce ketamine effects within 30 sec to at most 5 min 
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(Jansen, 1993). Intranasal and oral administration can take onset time up to 5 to 30 
min.  
1.4.2.5. Relevant dose range for ketamine’s dissociative effects 
1 to 2 mg/kg dosage can generate desired dissociative effects which can last 
up to 1 to 2 h (Sadove et al., 1971). But, ketamine dosage can be easily miscalculated 
and overdose occurs fast since tolerance builds up rapidly after repeated use (its 
potency weight for weight is actually stronger than cocaine). 
1.4.3. MK-801’s recreational use 
MK-801, brand name Dizocilpine, is less commonly used as a recreational 
drug than other arycyclohexylamines such as ketamine and PCP due to its high 
potency and very slow pharmacokinetics, both of which make dosage control hard 
and less predictable (Parsons et al., 1995). Also, MK-801 effects are not as 
“recreational” as other drugs and often users complained that the auditory 
hallucination is too strong and terrifying (Manahan-Vaughan et al., 2008). Due to 
MK-801’s unique pharmacokinetic property such as long and slow excretion rate, its 
residual side effects such as amnesia and impaired cognitive function last much 
longer than PCP and ketamine (MacDonald et al., 1991).  
1.4.4. New designer drugs 
As described above, it wasn’t long before PCP and ketamine gained world-
wide popularity as recreational drugs (Jansen, 1993). These days, in many countries 
including US, Canada and UK, regulation has been authourized to classify these 
drugs as controlled substances and their abuse has been banned on the streets (Roth 
et al., 2013; Morris, 2014). 
In order to circumvent such législations, “designer drugs” or “research 
chemicals” with dissociative effects have started to appear on the grey market from 
online vendors. These drugs exhibit similar hallucinogenic and cognitive effects as 
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those banned drugs but since their molecular structures were not registered in the 
legislation (different from arylcyclohexylamines like PCP and ketamine), 
manufacture, sale, circulation and consumption of these drugs were technically legal. 
Hence, another name for these drugs were “legal highs”.  
Since a lot of dissociative drugs had common features like tricyclic structure, 
many tricyclic compounds including 1,2-diarylethylamines were produced as legal 
highs. 1,2-diarylethylamines had an ethylamine nucleus as a core structure and 
vicinal aromatic substitutions (Hasegawa et al., 2014; Minakata et al., 2015). These 
drugs act on opioid receptors, monoamine transporters and NMDARs (Wink et al., 
2014; Wink et al., 2016). These 1,2-diarylethylamines such as 1-cyclohexyl-4-(1,2-
diphenylethyl)piperazine (MT-45), 1-(1,2-diphenylethyl)piperidine (diphenidine; 
DPH) were reported to have potent and long lasting dissociative effects such as 
hallucinations, tactile distortions, euphoria, derealization and depersonalization in 
anecdotal reports by users (http://www.bluelight.org/vb/threads/668291-The-Big-
and-Dandy-Diphenidine-Thread;http://www.erowid.org/chemicals/methoxphenidine/
methoxphenidine_timeline.php; http://drugs-forum.com/forum/showthread.php?
t=273812) (Wurita et al., 2014; Wallach et al., 2014; Sahai et al., 2018). 
1.4.4.1. Diphenidine 
 The first report of the synthesis of DPH, a type of tricyclic 1,2-
diarylethylamine, was far back in 1924, but it was not until the 2013 UK ban on 
arylcyclohexylamines-based drugs that DPH and other related diarylethylamines 
such as 2-methoxphenidine have gained popularity on the streets as designer drugs 
over their dissociative effects (Wink et al., 2016). High dose of DPH produces 
“bizarre somatosensory phenomena and transient anterograde amnesia.” (Morris & 
Wallach, 2014).  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1.4.4.2. Ephenidine 
N-Ethyl-1,2-diphenylethanamine (Ephenidine; Eph), is another psychoactive 
designer substance that became available on the grey market and rapidly spread 
throughout the streets due to its similar hallucinogenic behavioural effects to 
ketamine (Roth et al., 2013; Wink et al., 2015). Users have mentioned that they 




It hasn’t been too long since DPH and Eph have been banned in countries 
including Canada, UK and Sweden as a structurally related compounds such as (1R)-
N,N-Dimethyl-1,2-diphenylethanamine (lefetamine), a type of opioid drug. 
1.5. Aims of the study 
Aside from some NMDAR binding study results (Fig. 7), not a lot of 
information exists regarding the pharmacodynamics of these 1,2-diarylethylamine 
based “legal highs”. Their selectivity, mode of action and functional role regarding 
synaptic transmission are all unknown. Thus, indiscreet consumption by users who 
have bought these drugs from online vendors have caused fatal intoxication due to 
miscalculation of the doses or co-administration with other recreational drugs like 
marijuana or ecstasy. Therefore, it was quite urgent to study and report 
pharmacokinetic and pharmacodynamic characteristics of these dissociative drugs 
before more casualties occur. Thus, as part of this detailed study, Eph, DPH and 
several derivative compounds have been investigated as NMDAR antagonists, 
examining their selectivity and their effects on synaptic transmission and plasticity. 
Other aspects of the pharmacology of these compounds were carried out by 
collaborators, the results of which will be included in this dissertation.  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A.                     B. 
Fig. 1. Comparison of structures of two types of glutamate receptor: A. 
ionotropic B. metabotropic receptors (Taken from Kandel et al., 1991). 
A. Ionotropic receptors are comprised of 4 to 5 subunits to configure the 
complex. On the other hand, B. Metabotropic receptors are comprised of 
a G-protein coupled single polypeptide and connected to correlated ion 
channels (Kandel et al., 1991).  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A.                     B. 
Fig. 2. Comparison of structures of different types of ionotropic 
glutamate receptor: A. non-NMDA and B. NMDA receptor (Taken from 
Kandel et al., 1991). A. As can be seen in the figure itself, non-NMDA 
receptors structurally more simple than NMDA receptors. These 
receptors are activated by AMPA, kainite and quisqualate. Also, they 
have glutamate binding site and allow flows of Na+ and K+ ions and 
more permeable to these ions than Ca+2. B. NMDA receptors have each 
binding sites for glutamate, glycine, PCP, Mg+2, Zn+2 and polyamines. 
Opposite to non-NMDA receptors, NMDA receptors tend to be more 
permeable towards Ca+2 influx than Na+ ions (Kandel et al., 1991).  
- !  -56
Chapter 1. Introduction
 
Fig. 3. Representation of the GluN2A/B subunit histological patterns at 
the hippocampus formation (Taken from Petralia et al., 1994). Shown 
hippocampus slice was cut in sagittal sections and labeled with antibody 
to GluN2A/B. The left picture indicated as a is 2/3 of rostral 
hippocampus with low magnification (56 x). Areas indicated b on the 
right is presented with higher magnifications.  
* C1: CA1, C3: CA3, DG: Dentate Gyrus, arrowheads representing the 
pyramidal neuron’s apical dendrite.  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Fig. 4. Ketamine’s superior rapid and sustaining antidepressant effect has 
been demonstrated both in A. human study with depressed patients 
compared to placebo group (Taken from Berman et al., 2010) and in B. 
animal study using forced swim test compared to vehicle group (Taken 
from Autry et al., 2011).  





Fig. 5. Ketamine’s adverse effects. A. Long term abuse of ketamine 
could cause severe urinary tract toxicity and shrinkage of bladder (Taken 
from Tsai and Kuo, 2015). B. Illustration of ketamine’s “K-hole” effect 
which can produce unrealistic perception of reality and body detachment 
(floating) sensation.  




Fig. 6. Different types of agents which could exhibit ketamine-like fast 
antidepressant effect targeting glutamatergic receptors on presyantpic 
and postsynaptic terminals of synaptic cleft (Taken from Duman, 2014).  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Table. 1. Comprehensive List of glutamatergic receptor targeting 
antidepressant pipeline (Modified from Cortellis Disease Briefing 
Report).  
*NMDAR: NMDA receptor, DAT: Dopamine transporter, NET: Norepinephrine 
transporter, AMPAR PAM: AMPA receptor positive allosteric modulators, GluN2B 
NAM: GluN2B receptor negative allosteric modulator. P1: phase I, P2: phase II, P3: 
phase III  




DAT inhibitors; NET 
inhibitors
P3






















Mount Sinai Health 
System NMDAR antagonist P2
Ketamine hydrochloride National Institue of Mental Health NMDAR antagonist P2
Rislenemdaz Cerecor GluN2B antagonist P2
Tulrampator Servier AMPAR PAMs P2
AGN-241751 Allergan NMDAR modulators P1
AZD-8108 AstraZeneca NMDAR antagonist P1
EVT-103 Evotec GluN2B antagonist P1
TAK-653 Takeda AMPAR modulators P1
AMS-410 FA Amorsa Therapeutics NMDAR antagonist Preclinical
AMS-520 ER Amorsa Therapeutics NMDAR antagonist Preclinical
BMS-986163 Bristol-Myers Squibb GluN2B NAMs Preclinical
- !  -61
Chapter 1. Introduction
- !  -62
Chapter 2. 
Materials and Methods 
2.1. Introduction 
In this study, I used in vitro electrophysiological recordings made from rat 
and mouse parasagittal hippocampal slices as the primary method to investigate the 
pharmacodynamics of new designer compounds (DPH, 2-Cl-diphenidine (2-Cl-
DPH), 2-methoxy-diphenidine (2-MXP), 3-methoxy-diphenidine (3-MXP), 4-
methoxy-diphenidine (4-MXP), Eph) as well as ketamine’s metabolite (2S,6S)-6-
hydroxynorketamine ((2S,6S)-HNK) and (2R,6R)-6-hydronorketamine ((2R,6R)-
HNK) for comparing the characteristics of these compounds to those of the well-
investigated NMDAR antagonists such as ketamine, PCP and MK-801. In addition to 
in vitro field excitatory postsynaptic potential (fEPSP) and whole-cell patch clamp 
recordings performed by myself, receptor binding studies, in vivo pre-pulse 
inhibition (PPI) study as well as monoamine reuptake inhibition assays have been 
performed by the collaborators for the understanding of the pharmacokinetics of the 
compounds.  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2.2. Animal and Materials 
 All experiments with male Wistar and Sprague-Dawley rats (Charles River, 
UK) done in Bristol followed the guidelines of United Kingdom Animals (Scientific 
Procedures) Act (1986) and European Union Guidelines for Animal Care with the 
approval of the University of Bristol Ethics Committee. Experiments performed in 
Toronto with adult male C57BL/6 mice followed the guidelines of the Canadian 
Council on Animal Care (CCAC) with the approval of the University of Toronto 
Animal Care and Use Committee. Experiments performed in Seoul with P14 C57BL/
6 mice followed the guidelines of the Animal Care and Use Committee of Seoul 
National University. All the animals used in this study were on 12 h light/dark cycle 
with access to food and water ad libitum.  
 Information about all starting materials, reagents and solvents for synthesis, 
column chromatography and binding studies can be found in the Kang et al., 2017 
paper.  
2.3. Hippocampal slice preparation 
 Parasagittal hippocampal tissues sliced in 400 µm were prepared from rats 
and mice according to UK Home Office legislation (Schedule 1). Animals placed in 
an isoflurane vaporizer (Harvard Apparatus) received the lethal dose of isoflurane. 
Once the animals passed out, it was made sure that these animals were completely 
unconscious and then, animals were sacrificed by cervical dislocation. Brains were 
rapidly removed and placed in an ice-cold artificial cerebrospinal fluid (aCSF) 
composed of (in mM): 124 NaCl, 26 NaHCO3, 3 KCL, 1.4 NaH2PO4, 1 MgSO4, 2 
CaCl2, 10 D-Glucose, saturated with 95% O2 and 5% CO2. Brain was placed on top 
of the petri dish with half-frozen aCSF and olfactory bulb and cerebellum were 
removed. In order to stably glue the brain onto the vibrotome platform, small cuts on 
the lateral sides of the brain were made to flatten the gluing side. Hemisected brain 
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was laterally glued onto the vibrotome platform and a small Sylgard resin or agar 
block was placed behind each hemisphere for the stabilization. The platform was 
magnetically placed in vibratome chamber which was filled with ice-chilled, 
continuously oxygenated aCSF, and 400 µm thick slices were obtained (World 
Precision Instruments, USA / VT1000S, Leica Microsystems, USA). Whole slices 
were transferred into a new petri dish with fresh oxygenated aCSF for the dissection 
of hippocampal formation. Isolated hippocampal slices were then placed in an 
incubation chamber and stored for recovery at least 1 hour before starting 
experiments in a submerged recording chamber at 28 - 30°C.  
2.4. Recording Setup 
2.4.1. Recording Chamber 
 The extracellular electrophysiology was conducted in the CA1 region of rat 
or mouse hippocampal slices in submerged recording chamber (built-in house with 
three wells at the center) which was placed on top of the air table (Newport, USA) 
and surrounded by a Faraday cage for the most stable recording environment with 
minimum vibrations and electrical interference. aCSF, which was constantly heated 
(35°C) and oxygenated in the water bath (Clifton, UK), was drawn to the first well at 
a rate of 2~4 ml/min by pump (Watson-Marlow, USA) through a drip-feed system. 
aCSF flows through the center well where slices are placed on top of the nylon mesh, 
to the third well where waste aCSF is drawn out by a suction needle attached to a 
vacuum pump (Charles Austen Pumps, UK). Slices are anchored by horseshoe-
shaped wire that has net to prevent from floating in submerged chamber. The 
temperature of the aCSF was maintained at 30~32°C in the center well. The whole 
recording chamber was surrounded by warm and oxygenated water in order to 
humidify the slices and minimize the production of bubbles inside the chamber. The 
reference electrode made out of sliver-chloride wire which was connected to the 
headstage of the amplifier was placed under the nylon mesh at the center well 
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contacting aCSF. After the slices were positioned at the center well with the anchor, 
the level of aCSF was adjusted with the suction needle until the slices were entirely 
submerged. Submerge recording system has been chosen to increase the drug 
application time since some compounds required very long time period (~5 to 12 
hours) to completely inhibit NMDAR-mediated fEPSPs. The chamber was lit with an 
LED fibre optic light source (Schott, USA) and the Leica MS5 Stereomicroscope 
(Leica Microsystems, USA) was used to observe the slices. 
2.4.2. Electrodes 
The recording electrodes were pulled from borosilicate glass capillaries 
(Harvard Apparatus, UK; 1.5 mm O.D. x 0.8 mm I.D.) by P-97 Flaming Brown 
micropipette puller (Sutter Instruments, USA) and maintained at 3-6 MΩ. Concentric 
bipolar stimulating electrodes (FHC, USA) were used to stimulate two independent 
Schaffer collateral-commissural pathways every 30 seconds (0.03 Hz), alternating at 
the intervals of 15 seconds. The peak amplitude (pA) and slope of evoked fEPSPs 
were measured. Average of 4 consecutive fEPSPs over 2 min time period was plotted 
and at least 20 minutes of stable baseline was recorded before administration of any 
compounds or induction of synaptic plasticity.   
2.5. In Vitro fEPSP recording 
Two input system of extracellular field potential recording method was used 
to have intra-slice control pathway to check stable recording environment.  Thus, two 
above-mentioned stimulating electrodes were placed on each side of the Schaffer 
collateral-commissural pathways in the same distance away from the recording 
electrode (Fig. 7). Recordings were performed with Axoclamp 2 amplifier 
(Molecular Devices, USA), band-pass filtered at 0.1–3.0 kHz and digitized with 
BNC-2120 A/D board (National Instruments, USA) at a sampling rate of 20 kHz. 
WinLTP software (Anderson and Collingridge, 2007) was used for stimulation 
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protocol and acquiring and analyzing the measured signals online as well as offline 
(Fig. 8).  
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Fig. 7. Representation of the two input system for recording of the 
extracellular fEPSP in CA1 area of the hippocampal slice. A. The 
schematic figure of the CA1 field recording with the glass recording 
micro electrode (R) in between two stimulating electrodes (S1 & S2). B. 
The actual picture of the hippocampus slice of the C57BL/6 mice with 
all the electrodes in place. 
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Fig. 8. Representative example of fEPSP recording and trace on-line and 
off-line analysis via WinLTP program. A & B. Two trace graphs above: 
the blue trace illustrates an average of 4 fEPSPs trace recorded for 2 min. 
The purple trace represents the last averaged sample trace of 20 min 
baseline, with the Peak Amplitude (PA) and Slope (S) analysis indicated 
in red. Fibre Volley (FV) is also measured to confirm the consistently 
stable recording environment.  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2.5.1. NMDAR-mediated fEPSP inhibitory effect of test compounds 
To measure the functional activity of synaptic transmission in vitro, 
diphenidine (DPH) and ephenidine (Eph) along with the most conventional NMDAR 
antagonist, D-AP5 were tested on the extracellular NMDAR-mediated field 
excitatory postsynaptic potentials (fEPSP) from CA1 pyramidal neurons in 
hippocampal slices following Schaffer collateral stimulation. 
In order to measure the efficacies of compounds that block NMDAR 
response, it was necessary to isolate NMDAR-mediated fEPSP. After 30 min of 
stable baseline, a cocktail of compounds (PTX, NBQX, and CGP55845) were added 
to the normal aCSF to block AMPAR and GABAR-mediated events. With 2 ml/min 
perfusion rate, approximately 30 min later, AMPAR and GABAR response were 
abolished following the dramatic reduction in the response size. Therefore, in order 
to provide a measurable but sub-maximal NMDAR-mediated fEPSP, the stimulus 
strength was increased by at least 3-4 times. Usually, NMDAR response size grew up 
to 0.3 to 0.4 mV, which created unreliable comparison for slope values. Thus, the pA 
of the response was measured for detecting activity instead of measuring slope. 
When another steady 30 min baseline had been attained, test compounds were 
applied to the solution (Fig. 9 & 10).    
Using this experimental design, the reduction of the NMDAR-mediated 
fEPSP by competitive NMDAR antagonist, D-AP5 (10 μM) (n = 3) application was 
observed. D-AP5 resulted in the rapid and near maximal inhibitory effect and 
NMDAR-mediated fEPSP was inhibited up to 17 ± 0.74% of baseline; last 20 min 
averaged responses. The minuscule level of continuous leftover responses, measured 
as < 20% at the end of the experiment is feasibly appear to be the combination of 
stimulus artifact and non-glutamatergic synaptic transmission (Fig. 9. A). When 2 
μM of D-AP5 was applied, the isolated NMDAR-mediated fEPSP was blocked up to 
approximately 40% of the baseline, which was rapidly recovered within an hour after 
wash out (n = 6) (Fig. 9. B).  
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In a similar condition, DPH (10 μM) (n = 3) and Eph (30 μM) (n = 3) 
application was observed (Fig. 10). DPH 10 μM produced much slower reduction of 
the NMDAR-mediated fEPSP (inhibited up to 22 ± 0.42% of baseline). Equilibrium 
was not achieved during the 3 h superfusion (Fig. 10. A). Ephenidine showed faster 
kinetics than DPH but slower than D-AP5 reduction with NMDAR-mediated fEPSP 
inhibited up to 27 ± 0.87% of baseline measured from the last 20 min averaged 
responses (Fig. 10. B). 
For convenience, upcoming figures of the isolated NMDA response are 
illustrated with the responses before the isolation process omitted.  
2.5.2. Modulation of synaptic plasticity by NMDAR 
LTP was induced via theta-burst stimulation (TBS) protocol. Train of three 
TBS episodes with 10 second interepisode interval (IEI) was given and each episode 
consisted of 5 bursts at 5 Hz, with each burst of 5 pulses at 100 Hz. LTD was 
induced by low frequency stimulation (LFS) with 900 pulses at 1 Hz.  
To study the effect of ephenidine on LTP, slices were pre-incubated in control 
aCSF or aCSF containing 10 µM Eph for at least 2 h before fEPSPs were recorded. 
20 to 30 min of stable baseline was obtained and TBS (same protocol as in Park et 
al., 2016) was applied to the Schaffer collateral pathway. pA and the slope of the 
fEPSP in CA1 were measured for at least a further 40 min. Representative fEPSP 
recordings of LTP and LTD measured on-line are shown in figure 9. 
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Fig. 9. Graphs illustrating the methods used for isolating the NMDAR 
mediated component of the hippocampal fEPSP. A. The graph, which is 
an average of 3 experiments, illustrates the time course of the changes in 
amplitude of the fEPSP evoked by stimulation of the Schaffer collateral 
input as described in the text. Each point is the average of 4 consecutive 
fEPSPs. Following establishment of a stable baseline in control aCSF for 
a minimum of 30 min, NBQX 3 µM, CGP55845 10 µM and PTX 50 µM 
were added to the perfusate, for the time indicated by the open bar above 
the graph. When the resulting decrease in the amplitude of the AMPAR 
mediated potential has plateaued, the stimulus strength is increased 3-4x 
and a new baseline established for a further 30 min before adding the test 
compounds, typically for 3-5 h, to the perfusate, in this case D-AP5 10 
µM as illustrated by the solid bar above the graph. The traces above the 
graphs, a-d, are typical examples of the fEPSPs recorded at the time, 
marked on the graph with the appropriate lower case symbols. B. The 
graph illustrates a similar experiment (n=4) with D-AP5 2 µM but in this 
case the graph started after the block of the AMPAR and GABAR and 
the increase in stimulus strength to evoke the NMDAR mediated fEPSP, 
i.e. at the equivalent time to that indicated by the red dotted line in A. 
The graph also shows the reversibility of the NMDA antagonism and 
also serves to illustrate the viability and relative stability of the NMDAR 
dependent fEPSP over >5 h. Most figures in Chapter 3 use one or other 
of these two formats but normally with longer periods of compound 
application.  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Fig. 10. Effect of diphenidine and ephenidine on NMDAR-mediated 
hippocampal fEPSPs. A&B. Graphs showing the full recording protocol 
for isolating NMDAR mediated fEPSPs in CA1 region following 
Schaffer collateral stimulation. Following the stable 30 min baseline 
recording (a), AMPAR- and GABAR-mediated responses were inhibited 
pharmacologically (b), the stimulus strength was increased and a new 
baseline was obtained for the isolated NMDAR mediated fEPSPs (c) 
before administering the test compounds (DPH n=3 and Eph n=3) (d). 
Not the sharper (indicating faster response) shape of the trace from the 
AMPAR mediated fEPSP (a) versus wider (indicating slower response) 
shape of the trace from the NMDAR mediated (c) fEPSPs. 
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2.6. Whole-cell patch clamp recording 
Whole-cell patch clamp recordings of excitatory postsynaptic currents 
(EPSCs) were made from CA1 pyramidal cells, as described by Park et al. (2016), 
under visual guidance with IR-DIC optics (Zeiss, microscope; Hamamatsu, camera) 
(Fig. 11). Only experiments with access resistance (RA) variation less than 20% 
were selected to be integrated in the evaluation. The temperature of the recording 
chamber was conserved at 32°C. Borosilicate glass pipettes with a resistance range in 
between 3-5 MΩ were used as recording electrodes. The whole-cell internal solution 
was composed with (mM): 8 NaCl, 130 CsMeSO3, 10 HEPES, 0.5 EGTA, 4 Mg-
ATP, 0.3 Na3-GTP, 5 QX-314 and 0.1 spermine. The pH was fine-tuned to 7.2-7.3 
with CsOH and osmolarity to 285-290 mOsm/1. In order to quantify the pA of 
EPSCs throughout the holding voltage change from -60 mV to +60 mV, the Schaffer 
collateral pathway was stimulated at a frequency of 0.1 Hz. pA and initial slope of 
EPSCs and fEPSPs were measured using WinLTP (Anderson and Collingridge, 
2007). Five continous responses acquired at each holding potential were averaged to 
graph the current-voltage (I-V) relationship. Representative example of the sample I-
V curves and traces from typical experiments are shown in figure 12. Currents 
through NMDARs were pharmacologically isolated using 10 µM NBQX, 50 µM 
picrotoxin and 20 µM (+)-bicuculline. For these experiments, MgSO4 was omitted 
from the bath solution for at least 30 min before patching and replaced with 10 or 30 
µM ephenidine, 10 µM ketamine, 30 µM D-AP5 or 2 mM MgSO4. Rectification 
indices (RI) were analyzed from the EPSC values at -40 mV and +40 mV. Data were 
normalized to the baseline prior to the application of interested compounds, and are 
indicated as mean ± standard error of the mean (SEM) and evaluated using one-way 
ANOVA. 
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Fig. 11. Whole cell patch clamp recordings of EPSCs from hippocampal 
pyramidal neurons. A. Picture of the representative hippocampal 
pyramidal neuron used for whole cell patch clamp recordings of EPSC. 
B. Representative current-voltage plots for peak EPSCs of control 
(AMPAR+NMDA) currents (n=10) and C. NMDAR currents (n=9) from 
young adult SD rats. Both whole-cell recording was done in the presence 
of 50 µM Picrotoxin, 20 µM (+)-Bicuculline. NMDA IV curve was 
measured in the presence of 10 µM NBQX. D. Example traces of EPSCs 
recorded from - 60mV and + 60mV. Right after control IV curve has 
been drawn, 10 µM NBQX was added to the solution. 10 min. later, 
NMDA IV curve has been measured without adjusting response size. 
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2.7. Analysis  
 Since more than 10 compounds were used for comparison in this study, 
efforts were made to control experiments, sample sizes, obtain and interpret the 
results more accurately without any bias. For instance, experiments were randomized 
and interleaved with control experiments everyday so that the same animal 
hippocampal slices are used for more than at least 3 or 4 different compounds. Also, 
the order of compounds tested were adjusted everyday so the results were not 
affected by solution contamination from any drugs. At least 3 to 4 animals were 
targeted to be used for each experiments. However, since some of the compounds 
were provided from the collaborator’s lab in US, only 1 or 2 animals were tested for 
experiments with higher (50-100 µM) concentration.  
 Furthermore, WinLTP offline re-analysis program was used to measure fiber 
volley after LTD induction to exclude any experiments with significant fiber 
damages affecting data. Fiber volley represents the short deflection along the axons 
produced by activation of presynaptic fibers. In case of placing the stimulating 
electrode too deep within the slice, fibers would be damaged and decrease the 
response amplitude significantly. Any experiments exhibited more than 10% fiber 
volley changes after LFS or TBS was not included for the final dataset.  
 Results are presented with mean ± SEM. Responses were normalized to the 
baseline. Statistical significance was determined using (two-tailed) Student’s t-test 
when there were only two variables to compare; the level of significance is denoted 
as follows: *p < 0.05, **p < 0.01 and ***p < 0.0001. ANOVA followed by Post-hoc 
test (ie. Tukey’s test) was used for comparisons of more than two variables. The 
difference was considered significant when P < 0.05.  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Pharmacological and Electrophysiological Investigations 
of the Dissociative ‘Legal Highs’ and Traditional 
NMDAR Antagonists. 
 There has been an urgent need for defining the pharmacological and 
physiological characteristics of recently popularized 1,2-diarletyhlamines, including 
DPH and its derivatives as well as Eph due to increasing reports of overdose and 
lethal intoxications. While they manifest very similar hallucinogenic effects as illegal 
hallucinogens, these dissociative drugs have bypassed the legislation with different 
molecular structures compared to controlled substances such as ketamine and PCP. 
Distribution of these drugs have rapidly and imprudently spread throughout the 
streets and party scenes via the online vendors or through the gray market without 
any legal regulations. Hence the name “legal highs” were allocated to these designer 
drugs. 
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3.1. Introduction 
 Although PCP and ketamine are still used illegally as recreational drugs in 
many countries, their use, especially PCP’s has decreased to some extent due to 
lethal and long lasting adverse effects (Moeller et al., 2008). Ketamine, which is not 
as long lasting as PCP, has continued to be abused as a party drug (Freese et al., 
2002; Nutt et al., 2007; Morris and Wallach, 2014). Since many countries have 
executed fine measures to control the circulation and use of these substances, new 
chemicals with similar dissociative properties have started to appear (Roth et al., 
2013; Morris and Wallach, 2014). New designer compounds, DPH and its derivatives 
as well as Eph have been designed as alternative recreational drugs and sold in 
powder and tablet forms. These 1,2-diarylethylamine drugs are reported to exhibit 
dissociative effects like ketamine. Some of these 1,2-diarylethylamines such as 
lefetamine, remacemide and lanicemine are also known to have some clinical 
implications in some of the neurodegenerative and psychiatric disorders. Also, Eph, a 
two ringed N-ethyl-1,2-diphenylethylamine, has blossomed its presence with 
dissociative drug users. Other than a brief mention of PCP site binding properties of 
Eph in 1989, there has been limited informations on its synthesis process, 
mechanistic process, particular relationship to NMDAR antagonism or selectivity 
and its functional role (Thurkauf et al., 1989).  The molecular structure of standard 
channel blockers and newly designed drugs are depicted in Fig 12 and 13.  
 In fact, the appearance of Eph in the literature has been mentioned in 
chemical (Goodson et al., 1946) and pharmacological (Tainter et al., 1943) literature 
in 40s, and some usage has been reported in 2008 (Westphal et al., 2010). However, 
it has not been too long since Eph appeared in the gray markets of the internet 
retailers. Previously, Eph has been reported briefly in relation to MK-801 where its 
‘PCP binding site’ affinity was reported as 257 nM (Thurkauf et al., 1989). Eph’s fast 
acting property was also investigated relatively recently (Wink et al., 2014, 2015). 
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However, its involvement in the NMDAR function was not discussed in these 
previous studies as well as in any other research works as far as I am aware of. 
 Thus, this chapter is dedicated to addressing the pharmacodynamics of these 
drugs on synaptic transmission via extracellular recording methods in comparison 
with other NMDAR antagonists including ketamine and PCP. These investigations 
were performed not only to inform the properties of these drugs to users and 
governments but also in the hope of enlightening the unknown mechanism of 
ketamine’s antidepressant and dissociative effects. Potentially, a compound that 
demonstrates similar characteristics to ketamine could be studied further in the 
search for a superior antidepressant drug. 
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Fig. 12. Structures of established non-competitive NMDAR antagonists: 
Ketamine, PCP, MK-801 and memantine. 
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Fig. 13. Structures of new designer drugs: ephenidine, diphenidine and 
its derivatives 2-Cl-DPH, 2-MXP, 3-MXP and 4-MXP. 
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3.2. Results 
 The objective of this study is to investigate the potential NMDAR 
antagonistic properties of new street drugs pharmacologically and 
electrophysiologically and also to compare their actions to those of standard NMDA 
channel blockers with dissociative effects. Note that binding study experiments were 
performed by our collaborator Jason Wallach and his colleagues (Wallach et al., 
2016). Experiments performed for this particular chapter has been performed with 
P14 rat hippocampal slices.  
3.2.1. NMDAR-mediated fEPSP reduction time course of 9 compounds 
Using a protocol similar to that used in Fig 9 and 10 from chapter 2, after 30 
min of stable baseline, 1 and 10 µM of ketamine, PCP, MK-801, DPH, 2-Cl-DPH, 
Eph, 2-MXP, 3-MXP or 4MXP were added to the perfusate during collection of the 
isolated NMDAR response for up to 3 to 12 h, while recording the peak amplitude 
and area of the NMDAR-mediated fEPSPs. All compounds produced a rather slow 
reduction (time constant of inhibition between 20 and 227 min) of the NMDAR 
mediated fEPSP (Fig.14 - 18). At 10 µM concentration, ketamine, PCP and 2-MXP 
achieved a sub-maximal plateau level of inhibition, but other compounds didn’t. 
With 1 µM dose experiments, correspondingly, the slow kinetics of most tested drugs 
prevented demonstration of a sub-maximal plateau in a reasonable time window 
which made it difficult to assess the potencies. Even 12 hours of treatment was not 
sufficient to see the maximal inhibition effects for 1 µM concentration of several 
drugs (data not shown). Therefore, single exponential curves were fitted to the graph 
in order to extrapolate the fitted curves to investigate the half-time and the minimum 
plateau values acquired from the treatment of 1 and 10 µM dose. Interested 
compounds’ relative potencies were investigated according to the rates of antagonism 
and the plateau levels attained. Relative potency ranking of these compounds are as 
follows: MK-801 > PCP > Eph ≥ 2-Cl-DPH ≥ DPH ≥ 3-MXP ≥ 2-MXP > ketamine 
> 4-MXP. This is displayed in the superimposed single exponential curve fittings of 1 
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µM (Fig. 17) and 10 µM (Fig. 18) experiments. Each number of repetitions (n), half-
time and the minimum plateau values are presented in the figures (Fig. 14-16).  
To exemplify the differences in the time course of each of these drugs for 
inhibiting the NMDAR-mediated fEPSPs, a pair of compounds can be used. Thus, 
for instance, 1 µM ketamine showed that within 2 h of treatment, it could block the 
response to a near plateau level (Fig. 14. A), whereas other 1,2-diarylethylamines, 
such as 2-MXP 1 µM required more than 5 h to arrive at the near maximal inhibition 
level (Fig. 16. A). Furthermore, ketamine expressed dose-dependent trends in 
NMDAR-mediated fEPSP inhibition (including 5 µM concentration not shown here), 
producing a dose-dependent rate of onset and maximal inhibition. On the other hand, 
2-Cl-DPH exhibited similar maximal effect for both 1 and 10 µM if enough time was 
given (17 ± 4% and 16 ± 4% respectively; Fig. 15. B). From this investigation, it 
could be assumed that 2-Cl-DPH probably has more similar characteristics to 
MK-801, rather than to ketamine. MK-801 is known to be trapped inside and 
accumulate within the receptor with longer application times. Small increase in the 
response was seen right after 1 µM ketamine administration, which did not happen 
with any other compounds. Regarding application of AMPA and GABAergic 
response blockers, it could be caused by just fluctuation of the recording 
environment. Or it’s possible that the increase have been caused by non-
glutamatergic, such as opioids or monoamine receptor mediated responses caused by 
low concentration of ketamine since ketamine does act on dopamine site (Table 3). 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Fig. 14. Reduction of the NMDAR-mediated component of fEPSPs by 
three established uncompetitive NMDA antagonists, ketamine (A), 
MK-801 (B) and PCP (C). Each drug was superfused at 1 µM (blue) or 
10 µM (red) added to the aCSF. * The t1/2 and Min values represent the 
time to reach half the maximal response and the maximal effect. These 
values are derived from the single exponential curve-fitting presented in 
blue and red lines with 95% CI dotted lines as described in the Methods.  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Fig. 15. Reduction of the NMDAR mediated component of fEPSPs by 
three compounds of interest, DPH (A), 2-Cl-DPH (B) and Eph (C). Each 
drug was superfused at 1 µM (blue) or 10 µM (red) added to the aCSF. 
Other annotations as for the previous figure.  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Fig. 16. Reduction of the NMDAR-mediated component of fEPSPs by 
three MXP compounds, 2-MXP (A), 3-MXP (B) and 4-MXP (C). Each 
drug was superfused at 1 µM (blue) or 10 µM (red) added to the aCSF 
except for 4-MXP at 10 µM only. Other annotations as for the previous 
figure.  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Fig. 17. Time-course of inhibition of NMDAR-mediated fEPSPs for 
eight compounds at 1 µM, illustrated as single exponential curve fits. 
Note that for these experiments drugs were superfused for up to 12 h. N 
values are the same as the previous.  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Fig. 18. Time-course of inhibition of NMDAR-mediated fEPSPs for nine 
compounds at 10 µM, illustrated as single exponential curve fits. Note 
that for these experiments drugs were superfused for up to 5 h. N values 
are the same as the previous.  
- !  -91
Chapter 3. Pharmaco. & Electrophys. Investigations of ‘legal highs’ and NMDAR antagonists
3.2.2. NMDAR selectivity of new designer drugs 
To examine receptor selectivity and specificity, one of the DPH analogue was 
chosen to be superfused at 50 (n = 2) and 100 µM (n = 1) in the absence of AMPAR 
and GABAR antagonists for 1 h. 2-MXP, having the fastest activity rate amongst the 
new 1,2-diarylethylamine compounds, was selected for this purpose.  There were no 
differences in the results of 50 and 100 µM groups. Perfusion of 2-MXP did not 
inhibit AMPAR-mediated fEPSPs, rather, a small increase of the response was 
observed in few experiments which could be caused by the disinhibition of 
GABAergic interneurons from decreased NMDAR mediated excitation. Soon after 
the mixture of AMPAR and GABAR inhibitors were applied to the running aCSF 
along with 2 µM 2-MXP, the response dropped to 5.7 ± 0.55% of baseline. These 
data indicate 2-MXP to be at least 50 times more potent as an NMDAR antagonist 
than as an AMPAR antagonist (Fig. 19. A).  
For Eph receptor selectivity experiments, GABAR blockers were used from 
the beginning to prevent any increased activity of GABAergic interneuron. Based on 
my observation that 30 µM Eph application took 1 h 30 min to reach maximal 
inhibition (Fig. 10. B), a 50 µM concentration was used to show selectivity within 1 
h and 30 min (Fig. 19. B). An hour treatment of 50 µM Eph (n = 3) produced no 
significant reduction or enhancement of the peak amplitude of the recorded fEPSP. 
However, as depicted by the representative traces, the late NMDAR mediated 
component of the response was noticeably diminished. Addition of the AMPAR 
antagonist (NBQX with a reduced concentration of Eph), produced rapid inhibition 
of the remaining fEPSP (4.9 ± 0.2% of baseline), indicating Eph’s preferential action 
on NMDARs over AMPARs (Fig. 19. B). 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Fig. 19. Effect of 2-MXP and Eph on AMPAR- and NMDAR-mediated 
fEPSPs. A. Lack of inhibition of AMPAR mediated fEPSP by 50 and 
100 µM 2-MXP (open bar). The solid bar indicates time of supervision 
with 2-MXP, NBQX, CGP and PTX showing complete inhibition of 
glutamate receptor mediated fEPSPs. Note, in the sample traces at the 
top, the prolonged time course of the fEPSP in 2-MXP alone (b) 
compared with control (a). B. Lack of inhibition of AMPAR mediated 
fEPSP by 50 µM Eph (n=3) in an experiment conducted in the presence 
of the GABAR antagonists PTX and CGP (open bar). Note lack of 
increase in amplitude and duration of the fEPSP (b. vs. a.) relative to the 
experiment in A. Addition of NBQX 3 µM abolished the fEPSP (c). 
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3.2.3. Receptor binding affinities 
NMDAR binding affinities for the test compounds were performed by the 
collaborators James Wallach and his colleagues, who provided these compounds for 
us. The affinities were based on displacement of labelled [3H]-MK-801. The outcome 
is presented in Table 2. The rank order of potency was MK-801 > 2-Cl-DPH > DPH 
= 3-MXP > 2-MXP > PCP > Eph > ketamine > memantine > 4-MXP. It was 
interesting to see that the corresponding potency order of DPH and its three MeO-
isomers (DPH = 3-MXP > 2-MXP > 4-MXP) was commensurate with exchangeably 
replaced arylcyclohexylamines (PCP = 3-MeO-PCP > 2-MeO-PCP > 4-MeO-PCP) 
(Wallach, 2014). The structural resemblance between PCP and DPH (i.e. the benzyl-
piperidine part) as seen in Figure 13 and 14 could explain the match of their 
structure-activity relationship (SAR). Thus, it can be concluded that the overlapping 
parts of PCP and DPH act on the same PCP binding site of the NMDA channel pore.  
3.2.4. Monoamine reuptake inhibition 
1,2-diarylethylamines were first advertised to be acting on the dopamine site 
even though there were no scientific reports to support this site of action (https://
l e g a l - h i g h s - f o r u m . c o m / s e a r c h . p h p ?
action=results&sid=b34fc695dabf2ed166b68d3707c2cf0f&sortby=lastpost&order=d
esc). Thus, our group investigated the relationship of these compounds with 
dopamine and others via monoamine reuptake inhibition assay. IC50 values for DAT, 
NET and SERT of five compounds including DPH, 2-Cl-DPH and 2,3,4-MXP, 
screened at 10 µM, are presented in Table 3 to show the reuptake inhibitory 
functional potencies. We observed that these compounds didn’t have SERT affinity in 
the binding assays and in parallel, they showed lack of SERT functional activity in 
the reuptake inhibition assay except for the very weak 4-MXP activity. Similar to 
arylcycloalkylamines, 1,2-diarylethylamines also showed affinity at DAT and NET 
(Roth et al., 2013). It is possible that there might be advantageous therapeutic 
potential coming from these dual NMDAR and monoamine reuptake inhibitory 
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activity that could be applied to various neurological conditions including 
depression.  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Table. 2. NMDAR binding affinities of compounds of interest using 
displacement of [3H]-(+)-MK-801 binding to rat forebrain membranes. 
Mean ± SEM values (n=4) are given in nM. (Data from collaborators) 
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Table. 3. Inhibition of monoamine transporters by 1,2-diarylethylamines 
of interest. IC50 values for inhibition of individual monoamines uptake 
are given in µM. Values in parenthesis represent the Hill slopes. (Data 
from collaborators). Ketamine’s IC50 values are from previous articles 
(DAT: Keita et al., 1996; NET: Zhou and Sun, 2008; SERT: Martin et al., 
1988) 
Compound DAT IC50 (µM) NET IC50 (µM) SERT IC50 (µM)
Ketamine 4.6 290.7 20.2
DPH 1.99 (0.91) 9.25 (0.97) > 10
2-Cl-DPH 10.5 (0.65) 27.1 (1.02) > 10
2-MXP 30.0 (0.81) 35.2 (2.04) > 10
3-MXP 0.587 (0.92) 2.71 (0.95) > 10
4-MXP 2.23 (0.96) 22.5 (1.75) 19.0 (1.12)
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3.3. Discussion  
 In this study, I demonstrated that these new ‘legal highs’ which are abused 
as psychoactive drugs (Brandt et al., 2014), were relatively selective and potent 
NMDAR inhibitors. Our collaborators showed that some of these compounds also 
display modest dopamine, and norepinephrine reuptake inhibitory effects. Their rank 
order for the NMDAR binding affinities matched that of NMDAR mediated fEPSP 
inhibition, which gave a Spearman’s rank correlation coefficient of 0.78 (p = 0.0172, 
two-tailed). Prominently, some of these compounds including DPH and 2-Cl-DPH 
presented slower onset and offset effects which were comparable to the anecdotal 
reports of slow temporal action on human users. Taken together, these observations 
illustrate helpful information for possible therapeutic targeting, administrative 
legislation and misuse minimization strategies. 
3.3.1. Binding affinity results discrepancies 
 In the patent granted to 1,2-diarylethamines for treatment of neurotoxic 
injury, the binding affinities of DPH and its derivatives were explored (Gray and 
Cheng, 1989). The potency rank order of our study was similar to that of the previous 
studies but the binding affinities were quite different. Particularly, 2-Cl-DPH’s 
binding affinities in the present study was measured with nM affinity, which was 
much higher than other NMDAR inhibitors with pM affinity from the patent paper 
(Gray and Cheng, 1989). These discrepancies could have developed from the 
differences in the essential details of the experiments carried out in this study versus 
Gray and Cheng. In the patent paper, [3H]-TCP was used for the binding affinity 
study, whereas the more selective and established [3H]-MK-801 binding assay was 
used in the current study to label NMDAR from the rat forebrain (Wong et al., 1986; 
Tricklebank et al., 1989; Wong et al., 1988).  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Chapter 4. 
Comparison of old and new compounds as voltage-
dependent NMDA channel blockers. 
 I have demonstrated in the previous chapter that Eph is more potent and 
rapid NMDAR selective antagonist compared to other dissociative designer drugs 
such as DPH and its derivatives. Eph shows a ketamine-like concentration-dependent 
kinetics, and has been anecdotally reported to generate the most comparable 
ketamine-like euphoriant and hallucinogenic effects amongst available research 
chemicals (http://www.bluelight.org/vb/threads/766110-The-Big-amp-Dandy-
Ephenidine-%3F28N-ethyl-1-2-diphenylethylamine%3F29-Thread; http://
www.psychonaut.com/sintetici/56569-ephenidine.html). Following on from the 
neuroprotective characteristics of ketamine, this intriguing compound, Eph was also 
investigated in vitro for its functional role as a neuroprotective agent in neurotoxic 
injury such as in an ischemia model (Gray et al., 1989). Since the relationship 
between the voltage-dependent inhibition of NMDARs and the therapeutic potential 
of these compounds was reported (Frankiewicz et al., 1996), I was curious to 
compare the voltage dependency of Eph with that of other NMDAR blockers.   
Chapter 4. Comparison of old & new compounds as voltage-dependent NMDA channel blockers
4.1. Introduction 
 An endogenous channel blocker, the cation Mg2+, binds to the inner pore of 
the NMDARs (Mori et al., 1992) and leaves the channel when the membrane is 
depolarized (Nowak et al. 1984), for example from repetitive action potentials 
coming from the presynaptic site (Herron et al., 1986). This voltage dependent action 
of Mg2+ allows NMDAR to modulate synaptic transmission (Bliss and Collingridge, 
1993).  Also, it is well understood that differences in receptor affinity and voltage 
dependency could result in different therapeutic efficacy. A good example can be 
found in memantine and MK-801. Memantine has a low NMDAR affinity with 
proven therapeutic ability to improve cognitive impairments in intermediate to severe 
Alzheimer’s Disease patients. By constrast, MK-801, a high affinity compound on 
NMDAR, is known for its neuronal excitotoxic effect.  
 Here, whole-cell patch clamp recordings were used to compare the voltage-
dependent effect of Eph with other traditional NMDAR blockers such as Mg2+ ions, 
ketamine and D-AP5 at hippocampal CA1 synapses.  
4.2. Results 
 The objective of this chapter is to delve into the current-voltage relationship 
of NMDAR-mediated synaptic currents produced by ephenidine and other more 
traditional NMDA inhibitors such as Mg2+ ions, D-AP5 and ketamine in the hopes of 
understanding the mechanism behind psychotomimetic effects of ephenidine that 
resembles those of ketamine and hopefully predict the possible range of adverse 
effects. 
- !  -101
Chapter 4. Comparison of old & new compounds as voltage-dependent NMDA channel blockers
4.2.1. Current-voltage relationship of NMDAR blocker D-AP5 and 
Mg2+ 
Whole-cell patch clamp recordings were used on CA1 pyramidal neurons to 
construct I-V curves by varying the holding potentials from - 60 mV to +60 mV. 
Hippocampal slices were superfused with 3 µM of NBQX, 50 µM of PTX and 20 
µM of bicuculline containing aCSF in order to isolate NMDA receptor-mediated 
synaptic currents as discussed earlier. The aCSF perfusate contained no added Mg2+ 
ions, for at least 30 min before the addition of the test substances to the aCSF. The 
used substances were 2 mM Mg2+, 30 µM D-AP5 and a cocktail of compounds for 
complete NMDAR inhibition (100 µM D-AP5 and 5 µM L689,560) (Fig. 20). 2 mM 
Mg2+ presented typical properties of voltage-dependent channel blocker with less 
effect on outward currents compared to inward currents. This profile was quantified 
as RI value, the relative level of synaptic currents at +40 mV to -40 mV holding 
potentials (Fig. 22). In the control experiment without added Mg2+ ions, the RI was 
measured as 0.64 ± 0.03 and addition of 2 mM Mg2+ increased the RI value to 4.21 ± 
0.13. In contrast, D-AP5, a competitive channel blocker, decreased both inward and 
outward currents resulting in RI value similar to a level with Mg2+ free control (Fig. 
22). 
4.2.2. Current-voltage relationship of uncompetitive NMDA receptor 
blockers: ketamine and ephenidine 
To understand the voltage-dependent effect of ketamine and ephenidine, the 
same experiment protocols were performed, and 10 µM of ketamine and 10 or 30 
µM of ephenidine were added to the aCSF perfusate (Fig. 21). Since I have observed 
that the same concentration range of Eph and ketamine requires more than 1 hour to 
reach sub-maximal inhibition, hippocampal slices were pre-incubated with each drug 
for at least an hour before the whole-cell patch clamp recordings were initiated.  
The typical uncompetitive NMDAR antagonist, ketamine, produced a strong 
outward rectification. Eph presented fairly similar effect to ketamine at both 10 and 
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30 µM. For instance, the average current in 30 µM ephenidine was - 48 ± 8 pA at - 
40 mV while it was 133 ± 12 pA at + 40 mV. RI values were evaluated from the 
same current-voltage parameters, which were 1.27 ± 0.14 and 3.58 ± 0.33 for 10 µM 
and 30 µM Eph, respectively (Fig 22). Thus, it appears that 10 µM ephenidine has a 
similar voltage-dependent property with 10 µM ketamine which showed 1.96 ± 0.23 
of RI, while 30 µM Eph revealed an RI value similar to 2 mM Mg2+ which was 4.25 
± 0.31.  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Fig. 20. Whole cell patch clamp recordings of EPSCs from hippocampal 
pyramidal neurons. A. Peak EPSC I-V curves for no added Mg2+ (n = 26; 
black), 2 mM Mg2+ (n = 14; orange), 30 µM D-AP5 (n = 11; blue) and 
negative control NMDA blocker (100 µM D-AP5 and 5 µM L689,560 n 
= 10; gray) to the aCSF as indicated by the colored symbols. Examples 
of EPSCs recorded at +40 mV, 0 mV and -40 mV in the different drugs 
are shown above the plot. Y-axis of these sample traces were twice 
increased except the control trace for the convenience of comparison.  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Fig. 21. Whole cell patch clamp recordings of EPSCs from hippocampal 
pyramidal neurons. A. Peak EPSC I-V curves are illustrated for no added 
Mg2+ (n = 26; black), 10 µM ketamine (n = 12; green) or 10 µM (n = 10; 
pink) and 30 µM ephenidine (n = 21; red) to the aCSF as indicated by 
the colored symbols. Examples of EPSCs recorded at +40 mV, 0 mV and 
-40 mV in control, ketamine and 30 µM Ephenidine are shown above the 
plot.  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Fig. 22. Whole cell patch clamp recordings of EPSCs from hippocampal 
pyramidal neurons. A. Bar chart showing rectification indices (RI; 
+40mV/-40mV) for EPSCs recorded in aCSF with compounds shown in 
figure 22 and 23. B. Table showing the RI values for these drugs with 
mean SEM and compared using one-way ANOVA (vs. control) and level 
of significance is denoted as *** for p values < 0.0001  
Control Mg2+ D-AP5 Ketamine Ephenidine (10 uM)
Ephenidine 
(30 uM)
RI (+40/-40 mV) 0.64 ± 0.03 4.25 ± 0.31 0.83 ± 0.04 1.96 ± 0.23 1.27 ± 0.14 3.58 ± 0.33
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4.3. Discussion 
 In the present study, the RI values were measured from the current-voltage 
relationship as the ratio of EPSC amplitude between – 40 mV and + 40 mV. Eph and 
other NMDAR inhibitors were used to compare their voltage dependencies on 3-4 
weeks old rat hippocampal slices. The effects of Eph reported here were similar to 
the current and previous reports on ketamine in that both of these antagonists were 
strongly voltage-dependent (MacDonald et al., 1987; Davies et al., 1988). Compared 
to MK-801 and PCP, Eph shows less marked voltage-dependency and has similar 
pharmacodynamic properties to that of ketamine (Parsons et al., 1993). Eph’s actions 
also parallel that of ketamine in terms of dose-dependent and psychoactive effects. 
Also, the dose-dependent increase in RI suggests that the higher block of the channel 
at the – 40 mV of holding potential with increased concentration of Eph, whereas at 
+ 40 mV, the EPSC levels were relatively similar for both concentrations. This result 
might not be surprising due to the demonstrated characteristics of Eph in the 
previous chapter from dose-dependent effects on inward fEPSPs. Therefore, similar 
to ketamine, Eph can be considered to be the open channel blocker of NMDAR.  
Although Eph has not been reported as a psychotomimetic agent, it is quite 
feasible to assume that Eph could be included to be one, since many voltage-
dependent uncompetitive NMDA inhibitors exhibit schizophrenia-like 
psychotomimetic effects (reviewed by Lodge and Mercier, 2015). Anecdotal reports 
by users strongly support this, stating the appearance of dissociative effects (such as 
mood and cognitive function changes and strong hallucinations produced by Eph 
administration at doses ranging from 100 to 500 mg) and schizophrenia-like effects 
in high doses. This ketamine-like profile of Eph can put users in danger due to 
dissociative and analgesic effects of NMDAR antagonism (Morgan and Curran, 
2012). However, other than all these adverse effects, ketamine-like effects of Eph 
could be further investigated to see if it displays appropriate properties as a clinically 
relevant treatment such as antidepressant.  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Chapter 5. 
Synaptic Plasticity modulating role of old and new 
compounds 
 The previous chapter explored the voltage dependent characteristics of 
different NMDAR blocking compounds. One of the main effects of NMDAR 
antagonists is to reduce cognitive ability through modulating plasticity of synaptic 
responses. For instance, ketamine and PCP could interrupt normal learning and 
memory process by inhibiting induction of LTP at hippocampal CA1 and PFC 
synapses. Therefore, the aforementioned drugs were tested for their effects on 
synaptic transmission and plasticity.    
Chapter 5. Synaptic Plasticity modulating role of old and new compounds 
5.1. Introduction 
 Many of the devastating neuronal degenerating disorders such as 
Alzheimer’s disease manifest symptoms related to memory loss and cognitive 
malfunctioning as the result of the dysregulation in synaptic transmission and 
plasticity. Also, psychiatric disorders such as depression can be caused by the 
neuronal atrophy and reduced level of synaptic currents caused by chronic stress. 
One of the main reasons for these imbalances in neuronal connectivity is the 
glutamatergic system disturbance. Consequently, glutamate receptors have received 
copious amount of attention as the main targets of new drug development for 
neuropsychiatric diseases. As previously mentioned, ketamine became a successful 
candidate as an antidepressant that satisfied unmet needs of current drugs (reviewed 
in Abdallah et al., 2016) except for its dissociative and psychotomimetic effects. 
Thus, the ketamine-like drug, Eph was tested for its role in modulation of NMDAR-
dependent synaptic transmission and plasticity.  
 Most of the research on ketamine’s antidepressant performance has used the 
racemic form of (R,S)-ketamine comprising the enantiomers R- and S-ketamine. 
Compare to R-ketamine, S-ketamine presents higher affinity towards NMDARs 
(Ebert et al., 1997). Moreover, S-ketamine (product name: esketamine) was used in 
clinical trials for treatment resistant form of MDD in order to be evaluated for its 
efficacy in decreasing the symptoms of MDD such as anhedonia and perpetual and 
disturbing mood turmoil as well as suicidal ideation (ClinicalTrials.govIdentifier: 
NCT02133001). Intranasal administration of S-ketamine manifested outstanding and 
rapid antidepressant effects and was granted a fast track designation by the FDA. 
However, in 2016, an article published in Nature by Zanos et al. proposed that 
ketamine established its antidepressant effects via an NMDAR-independent (Zanos 
et al., 2016). Their hypothesis was that R- and S-ketamine’s metabolites (2R,6R) and 
(2S,6S)-HNK play a crucial role in long lasting antidepressant effects of ketamine. 
The authors pointed out that R-ketamine is not as potent as S-ketamine as an 
NMDAR blocker and that between the two metabolites, (2R,6R)-HNK derived from 
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R-ketamine is the one that is responsible for the behavioral and cellular effects of 
ketamine; the effects were suggested to be NMDAR-independent but involved 
AMPAR activation for ketamine’s antidepressant effect.  
 Since MDD pathogenesis is known to be affected by the hippocampal 
synaptic transmission dysfunction caused by neuronal excitotoxicity (Abdallah et al., 
2016), during the LTP and LTD experiments with Eph and ketamine, I also included 
(2R,6R)- and (2S,6S)-HNK to compare their roles, if any, in NMDAR-dependent 
synaptic plasticity coordination.  
5.2. Results 
 The aim of the present study was to measure Eph’s synaptic plasticity 
modulating effect as well as resolving the discrepancy on the underlying mechanism 
of ketamine’s rapid and sustaining antidepressant effects. When TBS was applied 
onto the Schaffer collateral pathway, a robust potentiation of the fEPSP slope was 
evoked in control slices whereas LFS produced a robust depression of the fEPSP 
slope in control slices. Most of the experiments done in this chapter were interleaved 
between control slices and slices incubated in different compounds as well as 
different doses of each drugs. All of the LTP and LTD induction blocking effects 
were compared by the average of the last 20 min responses of normalized fEPSP.  
5.2.1. Ketamine dose-dependently blocks LTP, but not LTD 
At the CA1 region of the P14 mouse hippocampal slice, TBS was applied to 
the Schaffer collateral pathway following at least 20 min of stable baseline for LTP 
induction. Control experiments were interleaved with slices pre-incubated and 
continuously perfused with 1, 3 or 10 µM ketamine (Fig. 25). As evident in the 
representative data of 10 µM ketamine treatment, LTP induction was completely 
blocked by the drug application (Fig. 23). This inhibitory effect of LTP by ketamine 
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was dose-dependent: an effect that could be seen immediately after the tetanus and 
which persisted (1 µM: 150.7 ± 1.8%; 3 µM: 101.3 ± 1.1%; 10 µM: 101.5 ± 1.2%), 
compared to the vehicle group (163.2 ± 1.3%) (Fig. 27).  
On the contrary, LTD was not fully blocked by even higher dose of ketamine. 
In the same condition as LTP experiments, LTD was induced by LFS after 20 min 
baseline was collected in new slices, but recorded from the same region of CA1 
hippocampal slices of P14 mice. LTD experiments were also interleaved with LTP 
experiments for cross-validation of the experimental conditions. 1, 3, 10 and 30 µM 
of ketamine were used and none of these treatments showed significant differences in 
the level of LTD compared to the vehicle group (vehicle group: 67.9 ± 0.4%; 1 µM: 
73.4 ± 0.8%; 3 µM: 65.0 ± 0.9%; 10 µM: 82.0 ± 0.6%; 30 µM: 72.0 ± 0.5%) (Fig. 24 
& 26) indicating that ketamine does not have a significant effect on LTD induction. 
These results suggest LTP and LTD have a different sensitivity to ketamine. 
In a dose-response analysis, there was a dose-dependent trend only for the 
effect of LTP blockade, whereas no such correlate was found in LTD (Fig. 27). 
D-AP5, a drug already well-known to block NMDAR-dependent synaptic 
plasticity, was tested in the same condition to check whether these negative results on 
LTD were because the LTD was an NMDAR-independent form (Fig. 26). While the 
vehicle group produced fEPSP response reductions up to 68.0 ± 0.6% of baseline 
after LFS, 100 µM D-AP5 completely blocked the induction of LTD (105.1 ± 1.8%). 
Since NMDAR blockade effects of 2 and 10 µM D-AP5 were demonstrated in 
previous studies (Fig. 9), a single representative 100 µM D-AP5 treatment 
experiment was performed to demonstrate the LTD blockade effect.  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Fig. 23. Representative example of the effect of ketamine on LTP of 
fEPSPs in the Schaffer collateral CA1 pathway. A. Representative traces 
of fEPSPs before a, 5 min after b and 40 min after c TBS of the input to 
CA1 neurons in the absence (black) or presence (red) of 10 µM ketamine 
are shown. The letters a, b and c indicate the times the traces were 
collected on the graph below, which shows the time-course of the 
normalized fEPSP slope values for each condition. TBS is indicated by 
the arrow at 20 min.  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Fig. 24. Representative example of effect of ketamine on LTD of fEPSPs 
in the Schaffer collateral CA1 pathway. A. Representative traces of 
fEPSPs before a, 5 min after b and 40 min after c LFS in the absence 
(black) or presence (red) of 10 µM ketamine or presence (blue) of 100 
µM D-AP5 are shown. The letters a, b and c indicate the times the traces 
were collected on the graph below, which shows the time-course of the 
normalized fEPSP slope values for each conditions. LFS is indicated by 
the capped line from 20 min to 35 min.*** = p < 0.0001.  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Fig. 25. Dose dependent inhibitory effect of ketamine on LTP of fEPSPs in the 
Schaffer collateral CA1 pathway. A. Graph showing the mean (+ SEM) normalized 
fEPSP slope values under control condition and from experiments on slices 
incubated in 1, 3 and 10 µM ketamine (n = 4 for each test condition). TBS is 
indicated by the arrow after 20 min of stable baseline. B. Bar graph depicting the 
average normalized fEPSP slope values (+ SEM) of the last 20 min of each 
experiments from the graphs above. Values were compared using one-way ANOVA 
(vs. control) and level of significance is denoted as *** for p values < 0.0001. 
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Fig. 26. Dose dependent inhibitory effect of ketamine on LTD of fEPSPs 
in the Schaffer collateral CA1 pathway. A. Graph showing the mean (+ 
SEM) normalized fEPSP slope values under control condition and from 
experiments on slices incubated in 1, 3, 10 and 30 µM ketamine as well 
as in 100 µM D-AP5. LFS is indicated by the capped line from 20 min to 
35 min. B. Bar graph depicting the average normalized fEPSP slope 
values (+ SEM) of the last 20 min of each experiments for above panel. 
Values were compared using one-way ANOVA (vs. control) and level of 
significance is denoted as *** for p values < 0.0001.  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Fig. 27. Inhibitory effects of ketamine (1, 3 and 10 µM for LTP and 1, 3, 
10 and 30 µM for LTD) on NMDA receptor mediated fEPSP slopes are 
illustrated in this concentration (log(ketamine)) - response curve. The 
IC50 values for these curves are 0.57 for LTP induction and could not be 
calculated for LTD induction.  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5.2.2. Eph dose-dependently blocks both LTP and LTD 
In the similar condition used above, 4 different doses (1, 3, 10, 30 µM) of 
Eph were used to evaluate its effect on synaptic plasticity modulation of P14 
animals. As seen in the representative and averaged data figures (Fig. 28, 29 & 30, 
31), 10 µM Eph blocked both LTP and LTD completely (Fig. 28 & 29) and this 
inhibitory effects was dose-dependent for both forms of synaptic plasticity (Fig. 30 
& 31). The 1 µM Eph-treated group did not show any difference in LTP induction 
(145.9 ± 1.4%) compared to the vehicle group (145.5 ± 1.3%). However, 3 µM Eph 
limited the fEPSP response increase to 120 ± 2.1%. 10 and 30 µM Eph blocked LTP 
induction entirely (10 µM: 101.4 ± 0.7%; 30 µM: 97.7 ± 1.4%) (Fig. 30). Similarly, 
LTD induction presented similar dose-dependency with Eph application. Compared 
to the vehicle group, which produced a normalized fEPSP response of 68.5 ± 1.0% of 
baseline level after LFS, 1, 3 and 10 µM Eph produced normalized fEPSP levels of 
72.6 ± 0.6%, 80.0 ± 0.4% and 92.9 ± 0.8%, respectively. The highest dosage used in 
this experiment, 30 µM produced almost complete block of LTD induction such that 
the normalized fEPSP level was 96.4 ± 0.5% (Fig. 31). The dose-response curve 
graphs of both LTP and LTD are compared in figure 32, with both curves 
demonstrating the dose dependent effect (Fig. 32). 
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Fig. 28. Representative example of the effect of Eph on LTP of fEPSPs 
in the Schaffer collateral CA1 pathway. A. Representative traces of 
fEPSPs before a, 5 min after b and 40 min after c TBS of the input to 
CA1 neurons in the absence (black) or presence (red) of 10 µM Eph are 
shown. The letters a, b and c indicate the times the traces were collected 
on the graph below, which shows the time-course of the normalized 
fEPSP slope values for 10 µM Eph. TBS is indicated by the arrow at 20 
min.  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Fig. 29. Representative example of the effect of Eph on LTD of fEPSPs 
in the Schaffer collateral CA1 pathway. A. Representative traces of 
fEPSP traces before a, 5 min after b and 40 min after c LFS of the input 
to CA1 neurons in the absence (black) or presence (green empty circle) 
of 10 µM ephenidine are shown. The letters a, b and c indicate the times 
the traces were collected on the graph below, which shows the time-
course of the normalized fEPSP slope values for 10 µM Eph. LFS is 
indicated by the capped line from 20 min to 35 min.  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Fig. 30. Dose dependent inhibitory effects of Eph on LTP of fEPSPs in 
the Schaffer collateral CA1 pathway. A. Graph showing the mean (+ 
SEM) normalized fEPSP slope values under control condition and from 
experiments on slices incubated in 1, 3, 10 and 30 µM Eph. TBS is 
indicated by the arrow at 20 min of stable baseline. B. Bar graph 
depicting the average normalized fEPSP slope values (+ SEM) of the last 
20 min of each experiments from the graphs above. Values were 
compared using one-way ANOVA (vs. control) and level of significance 
is denoted as *** for p values < 0.0001.  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Fig. 31. Dose dependent inhibitory effects of Eph on LTD of fEPSPs in 
the Schaffer collateral CA1 pathway. A. Graph showing the mean (+ 
SEM) normalized fEPSP slope values under control condition and from 
experiments on slices incubated in 1, 3, 10 and 30 µM ephenidine. LFS 
is indicated by the capped line from 20 min to 35 min. B. Bar graph 
depicting the average normalized fEPSP slope values (+ SEM) of the last 
20 min of each experiments for above panel. Values were compared 
using one-way ANOVA (vs. control) and level of significance is denoted 
as *** for p values < 0.0001.  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Fig. 32. Dose dependent inhibitory effects of Eph (1,3,10 and 30 µM) on 
fEPSP slope are illustrated in this concentration (log(Ephenidine)) - 
response curve. The IC50 values for these curves are 0.96 for LTP 
induction and 3.44 for LTD induction.  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5.2.3. Memantine’s inhibitory role in synaptic plasticity 
 The same four doses (1, 3, 10, 30 µM) of memantine, a drug currently used 
for the treatment of intermediate to severely affected patients of Alzheimer’s disease, 
were applied to mouse hippocampal slices to measure the LTP inhibitory role of 
memantine (Fig. 33). After 30 min of stable baseline was constantly monitored, TBS 
was given to the Schaffer collateral pathway of hippocampal slices. As with 
ketamine, memantine also blocked LTP induction dose-dependently. Similar to the 
vehicle group, which increased fEPSP responses up to 153.1 ± 2.0% of the 
normalized fEPSP value, the 1 µM memantine-treated group did not show blockade 
of LTP induction (145.2 ± 1.1%), and neither did the 3 µM group (162.9 ± 1.0%). 
However, for both 10 µM memantine (115.2 ± 1.5%) and 30 µM (105.6 ± 0.8%) 
memantine application significantly and dose-dependently blocked LTP induction. 
Only the highest dose (30 µM) of memantine was examined in LTD where it 
effectively blocked LTD induction (Fig. 33).  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Fig. 33. Memantine’s dose dependent synaptic plasticity inhibitory 
effects in the Schaffer collateral CA1 pathway. A. Graph showing the 
mean (+ SEM) normalized fEPSP slope values under control condition 
and from experiments on slices incubated in 1, 3, 10 and 30 µM 
memantine. TBS is indicated by the arrow at 20 min of stable baseline. 
B. Graph showing the memantine’s LTD block effect. Graph showing the 
mean (+ SEM) normalized fEPSP slope values in control pathway and 
LFS given pathway on slices incubated in 30 µM memantine. LFS is 
indicated by the capped line from 20 min to 35 min.  
- !  -125
Chapter 5. Synaptic Plasticity modulating role of old and new compounds 
5.2.4. (2R,6R)-HNK inhibits LTP with less potency than (2S,6S)-HNK 
 Ever since Berman et al. (2000) showed ketamine’s rapid antidepressant 
effects, there has been many attempts to reveal the mechanism behind this exciting 
effect of ketamine. Although a definite theory has not been set yet, it was broadly 
believed that ketamine’s NMDAR antagonistic property and its ability to modulate 
NMDAR-dependent synaptic plasticity was at the crux of this rapid and sustained 
antidepressant-like action, which is evident with even a single treatment of ketamine. 
However, this perspective was confronted by Zanos et al. (2016). Zanos and 
colleagues suggested that (2S,6S)- and (2R,6R)-HNK were metabolized from S- and 
R-ketamine respectively and that (2R,6R)-HNK was specifically critical for the long-
lasting antidepressant effect of ketmaine. More importantly, they proposed that the 
action was not NMDAR-mediated, but that changes in the AMPAR pathway 
mediated the (2R,6R)-HNK effects. We believe that there is not enough evidence to 
disregard the role of NMDARs (Refer to review by Collingridge et al., 2017). To 
determine their actions on NMDAR-dependent plasticity, (2S,6S)- and (2R,6R)-
HNK were each examined. At 1, 3 and 10 µM concentration (2S,6S)-HNK treatment 
induced significant dose-dependent inhibition of LTP (1 µM: 135.9 ± 2.4%; 3 µM: 
100.1 ± 2.8%; 10 µM: 105.8 ± 1.4% of baseline), compared to the same vehicle 
group (163.2 ± 1.3% of baseline) used in ketamine LTP experiments (Fig. 34). In the 
case of (2R,6R)-HNK, 10 and 30 µM application also showed significant reduction 
of LTP (10 µM: 128.7 ± 1.4%; 30 µM: 107.9 ± 1.9% of baseline), questioning the 
NMDAR-independent hypothesis of Zanos et al (Fig. 35). Thus, although less potent 
than (2S,6S)-HNK, (2R,6R)-HNK also revealed an ability to block LTP induction 
(Fig. 34 & 35). However, it should be noted that the sample numbers are small due 
to difficulties I experienced with producing stable baseline.  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Fig. 34. Representative effect of (2S,6S)-HNK on LTP of fEPSPs in the 
Schaffer collateral CA1 pathway. A. Representative traces of fEPSPs 
before a, 5 min after b and 40 min after c TBS of the input to CA1 
neurons in the absence (black) or presence (green) of 10 µM (2S,6S)-
HNK are shown. The letters a, b and c indicate the times the traces were 
collected on the graph below, which shows the time-course of the 
normalized fEPSP slope values for 10 µM (2S,6S)-HNK. TBS is 
indicated by the arrow at 20 min. B. Graph showing the mean (+ SEM) 
normalized fEPSP slope values under control condition and from 
experiments on slices incubated in 1, 3 and 10 µM (2R,6R)-HNK. TBS 
is indicated by the arrow at 20 min of stable baseline.  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Fig. 35. Representative effect of (2R,6R)-HNK on LTP of fEPSPs in the 
Schaffer collateral CA1 pathway. A. Representative traces of fEPSPs 
before a, 5 min after b and 40 min after c TBS of the input to CA1 
neurons in the absence (black) or presence (green) of 10 µM (2R,6R)-
HNK are shown. The letters a, b and c indicate the times the traces were 
collected on the graph below, which shows the time-course of the 
normalized fEPSP slope values for 10 µM (2R,6R)-HNK. TBS is 
indicated by the arrow at 20 min. B. Graph showing the mean (+ SEM) 
normalized fEPSP slope values under control condition and from 
experiments on slices incubated in 10 and 30 µM (2R,6R)-HNK. TBS is 
indicated by the arrow at 20 min of stable baseline. 
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5.3. Discussion 
 In this chapter, I have demonstrated the synaptic plasticity modulatory 
properties of five different compounds. Ketamine when applied in as little as 10 µM 
concentrations produced a complete inhibition of LTP induction. However, ketamine, 
even at a higher dose of 30 µM, had less sensitivity towards the inhibitory effect on 
LTD. Another dissociative NMDAR antagonist Eph did however, suppress induction 
of both LTP and LTD. The controversial metabolites (2S,6S)- and (2R,6R)-HNK also 
influenced LTP, contradicting the NMDAR-independent hypothesis of ketamine’s 
antidepressant effect proposed by the Zanos group. Although the results were carried 
out with several validating processes including having control pathway recordings in 
the same slice to confirm a stable experiment environment as well as carrying out 
most of the experiments in random order, there are still a few considerations to keep 
in mind with respect to interpretation of these results. 
 First, ketamine did not affect the induction of LTD compared to previous 
papers that had demonstrated the opposite outcome (Huang et al., 2016; Izumi and 
Zorumski et al., 2014). However, it is hard to make direct comparisons of these 
findings due to several differences in the experimental conditions. For instance, 
Huang and his colleagues induced LTD by 3 min perfusion of 20 µM NMDA while 
in this study, LFS was used to induce LTD. In addition, Huang et al. (2016) used 6-8 
weeks old mice whereas P14 mice were used in this study, which could create a 
considerable difference in the structure and NMDAR subunit receptor components of 
the brain. It has been demonstrated that the early postnatal days (P2-P15) are critical 
periods with NMDAR functional changes (Constantine-Paton and Cline, 1998; Cull-
Candy et al., 2001) such as decay kinetics of NMDAR becoming faster (Barth and 
Malenka, 2001) as well as an NMDAR subunit switch (mainly from GluN1/GluN2B 
subunit to GluN1/GluN2A composition) (Liu et al., 2004). Furthermore, in Huang et 
al. (2016) paper, only ventral hippocampal slices were used whereas dorsal and 
ventral hippocampal slices were used in this study. Izumi and Zorumski (2014) also 
used LFS to induce LTD but in P30-P32 rat, which also creates complication for 
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direct comparison between the results. I will attempt to explain possibilities behind 
the lack of effect of ketamine on LTD in more details in the next chapter.  
 Second, further studies are needed to draw more specific and significant 
conclusions from the (2R,6R)-HNK metabolite experiment due to small sample 
numbers. It was difficult to perform fEPSP experiments for (2R,6R)-HNK since 
responses were fluctuating a few minutes after beginning of the experiments, making 
it impossible to keep a stable baseline in many experiments. This adverse effect was 
not displayed by any other drug used in this study. For example, ketamine, (2R,6R)-
HNK and Eph would be tested in the same day with slices from the same animal but 
this loss of fEPSP stability was only seen in the presence of (2R,6R)-HNK. It should 
be noted that the concentration of the (2R,6R)-HNK was higher than achieved in the 
brain of ketamine-treated MDD patients whose peak plasma concentration of (2R,
6R)-HNK is expected to be as small as 23 nM (Zanos et al., 2018). I had pre-
incubated the slices with (2R,6R)-HNK at least for 2 to 3 hours before the 
experiments, i.e. the same as for other fEPSP-LTP experiments. This long application 
of high dose drug treatment might have affected AMPAR and caused abnormal 
function of AMPAR to generate this instability. Another possibility is that the 
specific batch of the compound I received could have been contaminated during 
dilution or aliquoting process. These issues prevented me from testing the effects of 
the metabolites on LTD. 
 The last point to consider is the dose-dependent blocking ability of new 
designer drug, Eph, on LTP and LTD induction. This potent action could explain 
Eph’s negative effects, which include cognitive deficits as well as memory 
impairment (Bliss and Collingridge, 1993). But also, Eph’s ketamine-like 
pharmacodynamic and LTP, LTD affecting properties could mean that there is a 
possibility for Eph to have a useful therapeutic profile that is relevant for depression. 
This is due to the potential importance of abnormal synaptic plasticity in the stressed 
and depressed state. During depression, many patients suffer from constant 
occurrences of negative thoughts and memories, which could be rooted from 
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persistent and/or excessive LTP and LTD. It has been suggested that blocking them 
with NMDAR inhibitors might be able to stop the depressive cycle of the 
pathological plasticity and uplift the mood (Collingridge et al., 2017).  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Chapter 6. 
Conclusion and Discussion 
 In this dissertation, I wished to capture the characteristics of the 
pharmacological and physiological properties of new designer drugs which showed 
dissociative effects in man but were not under any legislation, hence was termed with 
the title ‘legal highs’. As mentioned in the Introduction section, these new 
recreational drugs have been replacing the legislatively banned ketamine and PCP on 
the streets. They are known to possess high abuse liabilities due to their ketamine-
like hallucinogenic and psychedelic effects, and with that, various incidences of 
misuse of these drugs have created dangerous casualties. Since only limited studies 
have been conducted, their properties were barely understood, which made it even 
more dangerous for those who abuse them. Therefore, it was the primary goal for the 
present study to measure new drugs’ modulatory effects of synaptic transmission in 
the hippocampus. 
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 Therefore, mainly electrophysiolgocial and pharmacological tools were used 
to define the characteristics of these drugs. These results were compared to those of 
already well-established NMDAR antagonists to investigate possible physiological 
functions of these compounds. In the present study, these new drugs, especially Eph, 
appeared to have higher binding affinities towards NMDAR with selectivity and 
could regulate NMDAR-mediated synaptic transmission in the CA1 area of the 
hippocampus with voltage and dose-dependency as well as disrupting different forms 
of synaptic plasticity. With these results, I hope that I  have gathered enough 
information to illustrate similarities among the new designer drugs and other 
controlled substances so that these ‘legal highs’ should be considered to be 
categorized as “illegal highs” and as compounds that require as many cautions as 
other commonly abused dissociative drugs. 
 Furthermore, I have also investigated the synaptic plasticity inhibitory 
effects of memantine and ketamine as well as its metabolites (2S,6S)-HNK and (2R,
6R)-HNK, in the last section (Ch. 5) of this dissertation. Though these 4 compounds 
presented different onset dose, they all displayed modulatory role of LTP induction, 
even the controversial (2R,6R)-HNK compound as well. However, it appeared that 
ketamine could not block LTD induction at the CA1 region of the P14 mice 
hippocampal slices.  
6.1. Discussion 
 In this last chapter, I would like to discuss briefly on few intriguing points 
from present study. First off, although not mentioned on the Result sections, DPH 
and its derivative, 2-MXP demonstrated rather interesting outcomes during in vivo 
prepulse inhibition (PPI) behavior test performed by our collaborators, which is 
worth mentioning for its unexpected results. Secondly, I would like to elaborate 
possible reasons for ketamine’s LTP but not LTD specific inhibition more in detail.  
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6.1.1. Translational meaning of new ‘legal highs’ physiological 
characterization 
Most of the results from new compounds have now been published in the 
papers in collaboration with chemists from US (Wallach et al., 2016; Kang et al., 
2017). In the first paper, Wallach and his colleagues used the PPI test on DPH and 2-
MXP to measure the sensorimotor gating properties of these drugs.  
The PPI test is based on the phenomenon that a pre-insubstantial stimulus 
could modify the resulting acoustic startle response (ASR) from startle-inducing 
stimulus. This test could demonstrate pre-attentional sensory shifting ability of the 
compound of interest (Braff et al., 2001). Several NMDAR antagonists that display 
dissociative effects such as ketamine, PCP and MK-801 have been shown to interrupt 
PPI in rats (Mansbach and Geyer, 1989; Wiley et al., 2003). It has been suggested 
that NMDAR inhibition participates in cortical sensory overstimulation and cause 
abnormal sensory filtering procedure (Vollenweider and Geyer, 2001). This 
inadequate information transferring process could block proper PPI and might be 
involved in the hallucinogenic effects of NMDAR antagonists. 
Different doses, ranging from 1.25 to 30 mg/kg, of DPH treatment were used 
for PPI test. 10 mg/kg DPH application induced significant decrease in average PPI 
response (p<0.01, Tukey’s test; Fig 36. A1). This PPI blocking effect of DPH was 
also dose-responsive, demonstrating higher reduction of PPI with the highest dose 
(30 mg/kg) of DPH (p<0.0001; Fig 36. A2). DPH decreased the average of PPI with 
an ED50 = 9.5 mg/kg (95% CI 5.9–15.1 mg/kg), which corresponds to 31.5 (19.5– 
50.0) μmol/kg.  
On the other hand, 2-MXP required double the dose (20 mg/kg) of DPH to 
start disrupting PPI (p<0.0001; Fig 36. B2). Due to the lack of available compound, 
it was not possible to perform the full dose-response characterization of 2-MXP. 
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However, although not shown in this dissertation, our collaborators have reported 
that 20 mg/kg 2-MXP application significantly dropped the ASR from 175.9 ± 29.2 
to 78.8 ± 11.9 (p<0.0053). Therefore, in order to exclude the possibility that 2-
MXP’s effect on PPI was impaired by this largely diminished ASR magnitude due to 
floor effects (Geyer and Swerdlow, 2001), our collaborators have conducted studies 
(not shown) to measure the effect on PPI in subgroups of animals with matching 
startle levels. Eight animals were chosen from the vehicle and 20 mg/kg 2-MXP 
group with similar ASR. Fortunately, 20 mg/kg 2-MXP treatment significantly 
decreased average PPI while vehicle group did not produce any reduction 
(p<0.0001), indicating ASR change-independent PPI inhibiting effect of 2-MXP.  
In summary, DPH was more potent than 2-MXP in the in vivo PPI 
experiments. However, quite unexpectedly, these two compounds were less potent 
than values reported for other dissociative NMDAR antagonists such as PCP and 
ketamine. This was not anticipated since DPH displace [3H]MK-801 with 3-fold 
higher affinity than PCP and has 18-fold higher NMDAR binding affinities than 
ketamine (Table 2) but was considerably less potent than PCP and ketamine in PPI 
experiments in rodents (Halberstadt et al., 2016). This result is parallel in humans 
that reported less potency of DPH and 2-MXP compared to ketamine (Morris and 
Wallach, 2014). Further studies are needed to attend to this gap between in vitro and 
in vivo potency. But it might be possible to postulate that the pharmacokinetics of 
1,2-diphenylethylamines could take part in producing relatively low potency. It has 
been suggested that 1,2-diphenylethylamines have faster metabolization than 
arylcyclohexylamines (Wink et al., 2016). In fact, the possibility of different 
pharmacokinetic factors affecting physiological potency is an important considerable 
aspect in terms of therapeutic use for these compounds, notably on drug-drug 
interactions.  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Fig. 36. Effects of DPH and 2-MXP on in vivo pre-pulse inhibition (PPI) 
test. A1. Different doses (ranging from 1.25 to 10 mg/kg) of DPH were 
tested for the average PPI %. Each group was allocated with 10 
experiment animals. A2. Different doses (ranging from 2.5 to 30 mg/kg) 
of DPH were tested for the average PPI %. Each group was allocated 
with 9 to 10 experiment animals. B1. Different doses (ranging from 1.25 
to 10 mg/kg) of 2-MXP were tested for the average PPI %. Each group 
was allocated with 10 experiment animals. B2. 20 mg/kg of 2-MXP 
(n=12) was tested. *PPI values represent 3 average prepulse inhibition 
(mean ± SEM). (“Startle magnitude data were analyzed with one-factor 
ANOVA. Post-hoc analyses were performed using Tukey’s studentized 
range method. The alpha level was set at 0.05” Taken from Wallach et 
al., 2016).  
- !  -137
Chapter 5. Synaptic Plasticity modulating role of old and new compounds 
6.1.2. Ketamine’s LTP, but not LTD induction inhibitory action 
 In parallel with the previous in vivo study of ketamine blocking LTP (Stringer 
and Guyenet, 1983), the present study demonstrated ketamine’s dose-dependent  (1, 
3 and 10 µM) inhibitory effect of LTP induction in vitro. It has been suggested that 
this LTP blocking role of ketamine participates in interfering learning and memory in 
animal models (Sanger and Joly, 1991). On the other hand, interestingly, even dose 
as high as 30 µM of ketamine did not show complete block of LTD, which was quite 
unexpected result according to its NMDAR antagonistic effect. Other NMDAR 
antagonists such as AP5 could block LTP as well as LTD with the same dose range 
(Trommer et al., 1995). Also, ketamine and Eph have such similar pharmacokinetics 
and Eph blocked LTD induction in dose-dependent manner. I believe further studies 
are required to investigate and validate this result, but maybe it could be speculated 
that this unanticipated event arose from ketamine’s selective binding to a particular 
subunit of NMDAR. 
 Earlier studies’ are suggestive that at normal Mg2+ concentrations, ketamine 
has higher inhibitory selectivity towards GluN2C/D-containing NMDARs than 
GluN2A/B-containing NMDARs (Kotermanski and Johnson, 2009). This subtype 
specificity would be important in ketamine’s role in LTD regulation since extra-
synaptic NMDARs, which were hypothesized to play crucial role in LTD induction 
(Cull-Candy et al., 2001), are mainly composed of GluN2B-containing receptors 
(Vyklicky et al., 2014; Traynelis et al., 2010). Massey and colleagues have reported 
that LTD induction was increased when glutamate uptake was blocked, implying the 
diffusion of glutamate to extra-synaptic GluN2B-containing NMDARs are sufficient 
enough to elicit LTD (Massey et al., 2004). In the same study, intact LTD induction 
occurred even after synaptic NMDARs were blocked. Ketamine’s GluN2D specific 
action might present the dissociative effect, the biggest unmet need of ketamine as an 
antidepressant. The reasons behind this speculation are as follows. First of all, 
ketamine showed approximately 370 fold higher inhibitory potency towards short-
term potentiation (STP) than LTP (Ingram et al., 2018). STP is considered to be 
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important factor for working memory induction (Volianskis et al., 2013). Working 
memory functionality is required for reality and self perception. Therefore, it’s 
logical to feel disconnected and dissociated when ketamine inhibit STP and working 
memory gets hindered. Also, GluN2D receptors are mostly expressed in the PV-
expressing GABAergic interneurons, which fits distinctively with the fact that these 
specific neurons are found to be decreased in schizophrenic patients (Zhang and 
Reynolds, 2002). The receptor subtype specificity of Eph is unknown. This leaves 
the possibility that difference between ketamine and Eph on LTD may due to 
differences in subunit selectivity.  
 It is also interesting to see that GluN2B receptor blockers such as 
Rislenemdaz (Cerecor) or EVT-103 (Evotec) demonstrated ketamine-like rapid and 
sustaining anti-depressive responses with less desired adverse effects and are tested 
in clinical trials (Table 1). This might imply that GluN2B and GluN2D subunit 
containing NMDAR could both be accounted for the signaling cascade of decreased 
eEF2 phosphorylation, increased ERK/AKT, mTORC1 pathway, which ultimately 
leads to increased level of synaptic protein synthesis and ketamine’s unwanted 
psychedelic effect is only responsible from GluN2D subunit containing NMDAR.  
 Eph’s LTD blockade effect was also interesting in a sense that it contradicts 
the hypothesis suggested in 2013 by Malinow’s group, which stated that 
metabotropic NMDARs drive LTD by reducing intracellularly active synapses via 
conformational changes of the receptor itself and this process is independent of ion-
channel flow (Nabavi et al., 2013). However, Eph, an open-channel blocker which 
blocks ion flow through the NMDARs dose-dependently blocked LTD induction 
which arguably refutes their premise. 
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6.2. Future directions 
 There are several more experiments that could be performed that follow 
from the results of the present study. To mention a few, first of all, aforementioned 
ketamine’s LTP but not LTD affecting properties can be studied more thoroughly 
since ketamine’s unique rapid and long lasting antidepressant effect could be 
benefited from its capability of this precise and independent modulation of two 
different types of synaptic plasticity. Second of all, current study’s demonstration on 
(2R,6R)-HNK’s indicative action of NMDAR dependent synaptic plasticity 
inhibition requires further studies. Lastly, Eph’s special ketamine-like fast acting 
synaptic transmission modulation can be further studied in some behavior 
experiments to explore its possible therapeutic usages.  
6.2.1. Ketamine’s modulatory role on synaptic plasticity in relation 
to its antidepressant effect 
 Investigating the elusive mechanism of extraordinarily fast and sustained 
antidepressant action of ketamine could be equally important in understanding 
etiology of depression as well as finding new targets for development of novel drugs 
with rapid antidepressant effects but without ketamine-like adverse effects. In this 
regard, I believe the result of the current study showing the differential effect of 
ketamine on LTP versus LTD opens up a new direction for future research.  
 It would be interesting to see if ketamine’s LTP specific inhibition could 
disconnect the vicious loop of negative thoughts and memories that MDD patients 
suffer from. To investigate this feasibility, lateral habenula (LHb), an area, recently 
drew much attention for its crucial involvement in depression animal model (Yang et 
al., 2018) could be tested for changes in synaptic plasticity after congenital helpless 
behavior experiments. LHb neuronal burst firing was shown to be increased in this 
depression generating model which was blocked by ketamine treatment. This 
ketamine rescue effect in burst activity also went parallel with antidepressant effect 
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in both forced swim and sucrose preference tests (Yang et al., 2018). Thus, the level 
of LTD induction in this animal model before and after ketamine treatment should be 
able to provide further understanding of the involvement of synaptic plasticity in 
ketamine’s antidepressant effect.  
6.2.2. (2R,6R)-HNK’s involvement in NMDAR synaptic transmission 
 According to Zanos et al., 2016, (2R,6R)-HNK, a metabolite from the 
enantiomer R-ketamine primarily drove ketamine’s antidepressant action in NMDAR 
independent but AMPAR dependent manner. However, present study demonstrated 
its involvement in blockade of NMDAR dependent LTP induction. It should be taken 
into consideration, though, that the concentration used in this study is higher than the 
actual (2R,6R)-HNK achieved clinically after R,S-ketamine treatment to MDD 
patients as I mentioned earlier in the Chapter 5 discussion. 
 Due to small sample numbers and the issue of discrepancies in the 
concentration of the compound, further experiments are required to produce more 
concrete proof to dispute the NMDAR independent proposition, including repetition 
of current study as well as more pharmacological and physiological studies in 
NMDAR isolated conditions.  
 The binding studies have demonstrated that the affinity of (2R,6R)-HNK to 
displace 3H-MK-801 was greater than 100 µM, which is much higher compared to 
7-20 µM affinity of (2S,6S)-HNK (Moaddel et al., 2013), but like the case of 
memantine, (2R,6R)-HNK could have additional binding sites on NMDARs 
(Kotermanski and Johnson, 2009).  In addition, another study has already provided 
convincing evidences indicating that it is an NMDAR open-channel blocker (Suzuki 
et al., 2017). This study showed that 50 µM of (2R,6R)-HNK significantly reduced 
NMDAR-mediated mEPSCs in cultured hippocampal neurons. The same authors 
also suggested that Zanos and colleagues used inappropriate route of administration 
for the study. Zanos chose IP injection method for administration of ketamine but 
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since ketamine is metabolized in the liver, and IP treated drugs are primarily go 
through the liver (Lukas et al., 1971). Therefore, it cannot be disregarded that this 
route of administration could exaggerate the action of metabolites to the 
antidepressant action.  
 Furthermore, Zanos group suggested that (2S,6S)-HNK, a metabolite from 
the enantiomer, S-ketamine, which has higher NMDAR affinity, did not participate in 
antidepressant action of ketamine whereas its antidepressant effect is being proved in 
the clinical studies (Singh et al., 2015; Daly et al., 2018). In fact, Janssen Research & 
Development, LLC is currently developing a drug called esketamine, which is S-
ketamine (ClinicalTrials.gov Identifier: NCT01998958). FDA committee voted 
favorable for clinical trial results to be sufficient enough to prove its efficacy 
recently.  
6.2.3. Eph’s potential therapeutic indication 
 Eph’s such similar pharmacokinetic and physiological properties to 
ketamine might suggest that it could mimic ketamine’s unique antidepressant effect 
in behavior experiments such as forced swim, tail suspension test and/or sucrose 
preference tests. However, if Eph does not demonstrate such actions, it becomes even 
more interesting. So far, the biggest difference between ketamine and Eph is the 
blocking of LTD induction and if Eph does not show antidepressant effects, it 
becomes more convincing that the inhibition of LTP, but not LTD, plays on essential 
ketamine’s special antidepressant property.  
 In addition, since NMDAR is targeted with therapeutic potential for other 
neuropsychiatric disorders such as Alzheimer’s disease, Fragile-X, autism and 
schizophrenia (Parsons et al., 1999; Abdallah et al., 2016), Eph, a fast acting, 
voltage- and dose- dependent open channel blocker of NMDAR could be explored 
for further use in these other indications.  
- !  -142
Chapter 5. Synaptic Plasticity modulating role of old and new compounds 
6.3. Closing remarks 
 Here, I have described pharmacological and physiological characterizations 
of conventional NMDAR antagonists as well as new NMDAR antagonists with 
dissociative effects. For this study, I hope I have provided fundamental information, 
framework so to speak, to guide future research directions on NMDAR targeting 
novel therapeutics for long-term treatment, lacking adverse side effects with safer 
profiles. 
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